ClinicalTrials.gg
CompletedNCT03029247Updated Jun 3, 2021Results posted

Anemia Study in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Blood Pressure (ASCEND-BP)

A Phase 2 interventional study of Daprodustat and Epoetin alfa in Anaemia, sponsored by GlaxoSmithKline. Completed at 11 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
11th of 30
105 · median 76
Started
2017
with 3 others
Phase 2
10 of 30
none open now
Registered
18th of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 11th largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 2, and was the 18th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

This will be an open-label, randomized, parallel-group study in hemodialysis-dependent (HD) participants with anemia associated with chronic kidney disease (CKD), designed to compare the effects of daprodustat to epoetin alfa on blood pressure (BP). Participants will be screened for eligibility within 7 and 30 days prior to erythropoesis-stimulating agent (ESA) washout. Following a 2-week ESA washout period, on Day 1 participants will be randomized 1:1 and stratified by prior ESA dose before they undergo Acute Challenge 1, a single dose challenge to compare the acute effects on BP of the highest planned once-daily maintenance dose of daprodustat (24 milligrams [mg]) to the highest starting dose of epoetin alfa (100 units/kilogram [U/kg]). This will be followed by an 8-week hemoglobin (Hgb)-maintenance period, where doses of either daprodustat or epoetin alfa will be administered and adjusted. At the end of Hgb maintenance period, on Day 57 an Acute Challenge 2 will be repeated utilizing the same treatment dose administered in Acute Challenge 1; there will be a follow-up visit within 14+/-3 days after completing treatment.

03

Conditions studied

  • Anaemia

Browse trials for

Keywords

  • Anemia
  • Daprodustat
  • Blood pressure
  • ESA
  • CKD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • More than or equal to 40 years of age, at the time of signing the
  • Stable 8.5 to 11.5 grams per deciliter (g/dL) inclusive.
  • Dialysis frequency: On hemodialysis (HD, hemofiltration or hemodiafiltration) three-to five-times weekly for at least 4 weeks prior to screening.
  • A single pool Kt/Vurea >=1.2 based on a historical value obtained within 3 months prior to screening in order to ensure the adequacy of dialysis. If Kt/Vurea is not available, then an average of the last 2 values of urea reduction ratio should be at least 65 percent (%).
  • Treated with an ESA (epoetins or their biosimilars, darbepoetin, or methoxy polyethylene glycol [PEG]-epoetin beta) for at least 4 weeks prior to screening.
  • Participants may be on stable (\<=50% change in overall dose and compliance of 80% of prescribed doses in the 4 weeks prior to and including the screening period) maintenance oral or intravenous (IV; \<=100 mg/week) iron supplementation. If participants are on oral or IV iron, then doses must be stable for the 4 weeks prior to Washout.
  • Weight: Mid-week weight change between dialysis treatments \<5% as assessed post-dialysis at the Screening and Washout visits.
  • On at least 1 antihypertensive medication (excluding diuretics) and on that same medication and the same dose for at least 1 week prior to Washout.
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the consent form and the protocol.
  • Willing and able to wear ABPM device for at least 25 hours on two separate sessions.

Exclusion criteria

Exclusion Criteria

  • Planned change from HD to peritoneal dialysis within the study time period, or on home dialysis.
  • Planned for kidney transplant within the 16 weeks following the Screening visit.
  • An epoetin alfa dose of >=360 U/kg/week IV or >=250 U/kg/week subcutaneous (SC), or darbepoetin dose of >=1.8 micrograms (μg)/kg/week IV or SC, or methoxy PEG-epoetin beta dose of >=2.2 μg/kg/week within the 8 weeks prior to screening through Week -4.
  • Planned or recorded administration of Mircera (methoxy PEG-epoetin beta) within the 4 weeks prior to the .
  • Occurrence of myocardial infarction or acute coronary syndrome within 3 months prior to Washout.
  • Stroke or within 3 months prior to Washout.
  • Chronic Class 4 heart failure, as defined by the functional classification system diagnosed prior to Washout.
  • corrected for heart rate using Bazett's formula (QTcB) >500 milliseconds (msec), or QTcB >530 msec in participants with Bundle Branch Block. There is no QTc exclusion for participants with a predominantly paced rhythm.
  • Resting post dialysis SBP >160 millimeters of mercury (mmHg); or DBP >100 mmHg at screening or uncontrolled hypertension as determined by the investigator.
  • Presence of atrial fibrillation.
  • Active chronic inflammatory disease that could impact erythropoiesis (e.g., scleroderma, systemic lupus erythematosus, rheumatoid arthritis, celiac disease) diagnosed prior to Washout.
  • History of bone marrow aplasia or pure red cell aplasia.
  • Other causes of anemia including Pernicious anemia, thalassemia major, sickle cell disease or myelodysplastic syndrome.
  • (ALT) >2 times (ULN) (screening only) or >1.5 times ULN (screening only) or Current unstable liver or biliary disease per investigator assessment, generally defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
  • Major surgery (excluding vascular access surgery) within the 3 months prior to Washout or planned during the study.
  • Blood transfusion within the 8 weeks prior to Washout or an anticipated need for blood transfusion during the study.
  • Evidence of actively bleeding gastric, duodenal, or esophageal ulcer disease or gastrointestinal bleeding within the 8 weeks prior to Washout.
  • Clinical evidence of acute infection or history of infection requiring IV antibiotic therapy within the 8 weeks prior to Washout.
  • History of within the two years prior to screening through Day 1 or currently receiving treatment for cancer, or has a known complex kidney cyst (e.g., Bosniak Category IIF, III or IV) >=3 centimeters.
  • Participants with an upper arm diameter which cannot be measured by oscillometer/ sphygmomanometer cuff or for whom BP cannot be measured in the opposite arm of current vascular access.
  • History of severe allergic or anaphylactic reactions or to in the product.
  • Use of any prescription or non-prescription drugs or dietary supplements that are prohibited from screening until Washout.
  • The participant has participated in a clinical trial and has received an experimental investigational product within the 30 days prior to Day 1 or within 5 half lives of the investigational product prior to screening, whichever is longer.
  • Any other condition, clinical or laboratory abnormality, or examination finding that the investigator considers would put the participant at unacceptable risk, which may affect study compliance or prevent understanding of the aims or investigational procedures or possible consequences of the study.
  • A female participant is pregnant (as confirmed by a positive serum human chorionic gonadotrophin test for females of only), participant is breastfeeding, or participant is of reproductive potential and does not agree to follow one of the pre-specified options
  • Vitamin B12 at or below the lower limit of the reference range (may rescreen in a minimum of 8 weeks, following treatment).
  • Folate at \<2.0 nanograms/milliliter (ng/mL) (4.5 Nanomoles per Liter) (may rescreen in a minimum of 4 weeks, following treatment).
  • Ferritin at \<100 ng/mL
  • Transferrin saturation at \<20%.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Active comparator
    Participants receiving Epoetin alfa

    On Day 1, participants will undergo 24-hour Acute Challenge 1, in which participants will receive a single dose of 100 U/kg epoetin alfa IV. After completing Acute Challenge 1, participants will enter in an 8-week Hgb maintenance period. At the end of Hgb maintenance period, on Day 57, Acute Challenge 2 will be performed utilizing the same treatment dose administered in Acute Challenge 1.

    Drug: Epoetin alfa

  • Experimental
    Participants receiving Daprodustat

    On Day 1, participants will undergo 24-hour Acute Challenge 1, in which participants will receive 24 mg daprodustat. After completing Acute Challenge 1, participants will enter an 8-week Hgb maintenance period. At the end of Hgb maintenance period, on Day 57, Acute Challenge 2 will be performed utilizing the same treatment dose administered in Acute Challenge 1.

    Drug: Daprodustat

Interventions

  • Daprodustat will be available as oral tablets at unit dose strength of 1, 2, 4, 6, 8 and 10 mg.

  • Epoetin alfa will be administered according to local labelling and clinical practice guidelines to keep Hgb in the target range (10.0-11.0 g/dL)

06

What researchers measure

Primary outcomes

  1. Average of Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM) Over 6-hour Post Dosing on Day 57

    The effect of daprodustat and epoetin alfa on blood pressure was compared using ABPM after 8 weeks of Hgb maintenace therapy on Day 57. Analysis was based on "analysis of covariance (ANCOVA) with terms for treatment, prior erythropoiesis-stimulating agent (ESA) dose (low/high), post-Hemodialysis dependent (HD)/pre-AC 1 SBP, difference between post-HD/pre-AC 2 SBP and post-HD/pre-AC 1 SBP and treatment by difference in post-HD SBP between AC 1 and 2 interaction." Least square (LS) mean of 6 hour average SBP post AC2 on Day 57 and its corresponding standard error has been presented.

    Time frame: Up to 6 hours post dose on Day 57

Secondary outcomes

  1. Average of SBP, Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) Measured by ABPM Over 6-hour Post Dosing on Day 1

    The initial effect of daprodustat and epoetin alfa on blood pressure was compared using ABPM over 6 hour post-dosing on Day 1. Analysis was based on ANCOVA with terms for treatment, prior ESA dose (low/high), post-HD/pre-AC1 SBP, DBP and MAP. LS mean of 6 hour average SBP, DBP and MAP post AC1 on Day 1 and its corresponding standard error has been presented.

    Time frame: Up to 6 hours post dose on Day 1

  2. Average of Heart Rate (HR) Measured by ABPM Over 6 Hour Post Dosing on Day 1

    The initial effect of daprodustat and epoetin alfa on HR was compared using ABPM over 6 hour post-dosing on Day 1. Analysis was based on ANCOVA with terms for treatment, prior ESA dose (low/high), post-HD/pre-AC1 HR. LS mean of 6 hour average HR post AC1 on Day 1 and its corresponding standard error has been presented.

    Time frame: Up to 6 hours post dose on Day 1

  3. Area Under the Effect Curve (AUEC) of SBP, DBP and MAP Measured by ABPM Over 24-hour Post Dosing on Day 1

    The initial effect of daprodustat and epoetin alfa on blood pressure was compared using AUEC of SBP, DBP and MAP measured by ABPM over 24-hour post dosing on Day 1. Analysis was based on ANCOVA with terms for treatment and prior ESA dose (low/high). LS mean of AUEC up to 24 hours post dose on Day 1 and its corresponding standard error has been presented.

    Time frame: Up to 24 hours post dose on Day 1

  4. AUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 1

    The initial effect of daprodustat and epoetin alfa on HR was compared using AUEC of HR measured by ABPM over 24-hour post dosing. Analysis was based on ANCOVA with terms for treatment and prior ESA dose (low/high). LS mean of AUEC up to 24 hours post dose on Day 1 and its corresponding standard error has been presented.

    Time frame: Up to 24 hours post dose on Day 1

  5. Average of DBP and MAP Measured by ABPM Over 6-hour Post Dosing on Day 57

    The effect of daprodustat and epoetin alfa on blood pressure was compared using ABPM over 6 hour post-dosing after AC2 on Day 57. Analysis was based on ANCOVA with terms for treatment, prior ESA dose (low/high), post-HD/pre-AC1 DBP and MAP, difference between post-HD/pre-AC2 DBP and MAP and post-HD/pre-AC1 DBP and MAP and treatment by difference in post-HD DBP and MAP between AC1 and 2 interaction. LS mean of 6 hour average DBP and MAP post AC2 on Day 57 and its corresponding standard error has been presented.

    Time frame: Up to 6 hours post dose on Day 57

  6. Average of HR Measured by ABPM Over 6 Hour Post Dosing on Day 57

    The effect of daprodustat and epoetin alfa on HR was compared using ABPM over 6 hour post-dosing. Analysis was based on ANCOVA with terms for treatment, prior ESA dose (low/high), post-HD/pre-AC1 HR, difference between post-HD/pre-AC2 HR and post-HD/pre-AC1 HR and treatment by difference in post-HD HR between AC1 and 2 interaction. LS mean of 6 hour average HR post AC2 on Day 57 and its corresponding standard error has been presented.

    Time frame: Up to 6 hours post dose on Day 57

  7. AUEC of SBP, DBP and MAP Measured by ABPM Over 24-hour Post Dosing on Day 57

    The effect of daprodustat and epoetin alfa on blood pressure was compared using AUEC of SBP, DBP and MAP measured by ABPM over 24-hour post dosing on Day 57. Analysis was based on ANCOVA with terms for treatment and prior ESA dose (low/high). LS mean of AUEC up to 24 hour post dose on Day 57 and its corresponding standard error has been presented.

    Time frame: Up to 24 hours post dose on Day 57

  8. AUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 57

    The effect of daprodustat and epoetin alfa on HR was compared using AUEC of HR measured by ABPM over 24-hour post dosing on Day 57. Analysis was based on ANCOVA with terms for treatment and prior ESA dose (low/high). LS mean of AUEC up to 24 hour post dose on Day 57 and its corresponding standard error has been presented.

    Time frame: Up to 24 hours post dose on Day 57

  9. Change From Pre-dose in SBP, DBP and MAP at Day 1

    The change from pre-dose in SBP, DBP and MAP was measured using ABPM to compare the initial effect of daprodustat to epoetin alfa after AC1 on Day 1. Change from pre-dose at each timepoint is calculated as measurement at post-dose minus pre-acute challenge 1 measurement.

    Time frame: Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24 hours post-dose

  10. Change From Pre-dose in HR at Day 1

    The change from pre-dose in HR was measured using ABPM to compare the initial effect of daprodustat to epoetin alfa after AC1 on Day 1. Change from pre-dose at each timepoint is calculated as measurement at post-dose minus pre-acute challenge 1 measurement.

    Time frame: Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24 hours post-dose

  11. Plasma Concentrations of Daprodustat

    Blood samples were collected at indicated time points for the concentrations of daprodustat.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57

  12. Plasma Concentrations of Metabolite GSK2391220

    Blood samples were collected at indicated time points for the concentrations of metabolite GSK2391220.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57

  13. Plasma Concentrations of Metabolite GSK2506104

    Blood samples were collected at indicated time points for the concentrations of metabolite GSK2506104.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57

  14. Plasma Concentrations of Metabolite GSK2487818

    Blood samples were collected at indicated time points for the concentrations of metabolite GSK2487818.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57

  15. Plasma Concentrations of Metabolite GSK2506102

    Blood samples were collected at indicated time points for the concentrations of metabolite GSK25206102.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57

  16. Plasma Concentrations of Metabolite GSK2531398

    Blood samples were collected at indicated time points for the concentrations of metabolite GSK2531398.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57

  17. Plasma Concentrations of Metabolite GSK2531401

    Blood samples were collected at indicated time points for the concentrations of metabolite GSK2531401.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57

  18. Maximum Plasma Concentration (Cmax) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401

    Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat and its metabolites GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401. PK parameters were analyzed using standard non-compartmental analysis.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57

  19. Time of Occurrence of Cmax (Tmax) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401

    Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat and its metabolites GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401. PK parameters were analyzed using standard non-compartmental analysis.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57

  20. Terminal Phase Half-life (t1/2) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401

    Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat and its metabolites GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401. PK parameters were analyzed using standard non-compartmental analysis.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57

  21. Area Under Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401

    Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat and its metabolites GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401. PK parameters were analyzed using standard non-compartmental analysis.

    Time frame: Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57

Other outcomes

  1. Number of Participants With Any Serious Adverse Events (SAEs)

    Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.

    Time frame: Up to Week 10

  2. Number of Participants With Treatment Emergent Common (>=2%) Non-serious Adverse Events (Non-SAEs)

    An AE is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with study treatment. Number of participants with treatment emergent common (\>=2% non-SAEs in each arm) non-SAEs has been presented.

    Time frame: Up to Week 8

  3. Number of Participants Who Discontinued the Study Treatment

    Number of participants who discontinued the study treatment due to any reason are presented. The reasons for discontinuation included adverse events, protocol specified withdrawal criteria met, physician decision and withdrawal by participant.

    Time frame: Up to Week 10

  4. Absolute Values for Clinical Chemistry Parameters: Albumin and Protein

    Blood samples were collected for the analysis of clinical chemistry parameters including albumin and protein. Baseline value (Day1) is the latest non-missing pre-dose assessment.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  5. Absolute Values for Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)

    Blood samples were collected for the analysis of clinical chemistry parameters including ALP, ALT and AST. Baseline value (Day1) is the latest non-missing pre-dose assessment.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  6. Absolute Values for Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin and Indirect (Indrt) Bilirubin

    Blood samples were collected for the analysis of clinical chemistry parameters including direct bilirubin, total bilirubin and Indrt bilirubin. Baseline value (Day1) is the latest non-missing pre-dose assessment.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  7. Absolute Values for Clinical Chemistry Parameters: Calcium Corrected for Albumin (CCA), Glucose, Potassium, Phosphate and Sodium

    Blood samples were collected for the analysis of clinical chemistry parameters including CCA, glucose, potassium, phosphate and sodium. Baseline value (Day1) is the latest non-missing pre-dose assessment.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  8. Change From Baseline Values for Clinical Chemistry Parameters: Albumin and Protein

    Blood samples were collected for the analysis of clinical chemistry parameters including albumin and protein. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  9. Change From Baseline Values for Clinical Chemistry Parameters: ALP, ALT and AST

    Blood samples were collected for the analysis of clinical chemistry parameters including ALP, ALT and AST. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  10. Change From Baseline Values for Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin and Indrt. Bilirubin

    Blood samples were collected for the analysis of clinical chemistry parameters including direct bilirubin, total bilirubin and indrt. bilirubin. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  11. Change From Baseline Values for Clinical Chemistry Parameters: CCA, Glucose, Potassium, Phosphate and Sodium

    Blood samples were collected for the analysis of clinical chemistry parameters including CCA, glucose, potassium, phosphate and sodium. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  12. Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes

    Blood samples were collected for the analysis of hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Baseline value (Day1) is the latest non-missing pre-dose assessment.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  13. Absolute Values for Hematology Parameter: Hematocrit

    Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value (Day1) is the latest non-missing pre-dose assessment.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  14. Absolute Values for Hematology Parameters: Erythrocytes and Reticulocytes

    Blood samples were collected for the analysis of hematology parameters: erythrocytes and reticulocytes. Baseline value (Day1) is the latest non-missing pre-dose assessment.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  15. Absolute Values for Hematology Parameters: Hemoglobin and Erythrocyte Mean Corpusclar Hemoglobin Concentration ( Ery. MCHC)

    Blood samples were collected for the analysis of hematology parameters: hemoglobin and ery.MCHC. Baseline value (Day1) is the latest non-missing pre-dose assessment.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  16. Absolute Values for Hematology Parameter: Ery. Mean Corpuscular Hemoglobin (MCH) and Reticulocyte Corpuscular Hemoglobin Content (CHr)

    Blood samples were collected for the analysis of hematology parameter: ery.MCH and CHr. Baseline value (Day1) is the latest non-missing pre-dose assessment.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  17. Absolute Values for Hematology Parameter: Ery. Mean Corpuscular Volume (MCV)

    Blood samples were collected for the analysis of hematology parameter: ery.MCV. Baseline value (Day1) is the latest non-missing pre-dose assessment.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  18. Absolute Values for Hematology Parameter: Erythrocyte Distribution Width

    Blood samples were collected for the analysis of hematology parameter: erythrocyte distribution width. Baseline value (Day1) is the latest non-missing pre-dose assessment.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  19. Change From Baseline Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes

    Blood samples were collected for the analysis of hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  20. Change From Baseline Values for Hematology Parameter: Hematocrit

    Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  21. Change From Baseline Values for Hematology Parameters: Erythrocytes and Reticulocytes

    Blood samples were collected for the analysis of hematology parameters: erythrocytes and reticulocytes. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  22. Change From Baseline Values for Hematology Parameters: Hemoglobin and Ery. MCHC

    Blood samples were collected for the analysis of hematology parameters: hemoglobin and ery.MCHC. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  23. Change From Baseline Values for Hematology Parameters: Ery. MCH and CHr

    Blood samples were collected for the analysis of hematology parameter: ery.MCH and CHr. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  24. Change From Baseline Values for Hematology Parameter: Ery. MCV

    Blood samples were collected for the analysis of hematology parameter: ery.MCV. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  25. Change From Baseline Values for Hematology Parameter: Erythrocyte Distribution Width

    Blood samples were collected for the analysis of hematology parameter: erythrocyte distribution width. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Days 29, 57 and Week 10

  26. Absolute Values for Electrocardiogram (ECG) Mean Heart Rate

    Full 12-lead ECGs were obtained in supine position using an ECG machine to measure mean heart rate. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.

    Time frame: Baseline (Day 1-predose) and at Day 1: 24 hours; Day 57: pre-dose; Day 57: 24 hours and Week 10

  27. Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval Corrected for Heart Rate (QTc) and QT Interval Corrected for Heart Rate Using Bazett's Formula (QTcB)

    Full 12-lead ECGs were obtained in supine position using an ECG machine to measure ECG parameters: PR interval, QRS duration, QTc interval and QTcB. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.

    Time frame: Baseline (Day 1-predose) and at Day 1: 24 hours; Day 57: pre-dose; Day 57: 24 hours and Week 10

  28. Change From Baseline Values for ECG Mean Heart Rate

    Full 12-lead ECGs were obtained in supine position using an ECG machine to measure mean heart rate. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1-predose) and at Day 1: 24 hours; Day 57: pre-dose; Day 57: 24 hours and Week 10

  29. Change From Baseline Values for ECG Parameters: PR Interval, QRS Duration, QTc and QTcB

    Full 12-lead ECGs were obtained in supine position using an ECG machine to measure ECG parameters: PR interval, QRS duration, QTc interval and QTcB. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1-predose) and at Day 1: 24 hours; Day 57: pre-dose; Day 57: 24 hours and Week 10

  30. Absolute Values for Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Vital signs including SBP and DBP were measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.

    Time frame: Baseline (Day 1, predose) and at Day 1: 3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis

  31. Absolute Values for Temperature

    Temperature was measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.

    Time frame: Baseline (Day 1, predose) and at Day 1: 3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis

  32. Absolute Values for Pulse Rate

    Pulse rate was measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.

    Time frame: Baseline (Day 1, predose) and at Day 1:3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis

  33. Change From Baseline Values for Vital Signs: SBP and DBP

    Vital signs including SBP and DBP were measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1, predose) and at Day 1: 3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis

  34. Change From Baseline Values for Temperature

    Temperature was measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1, predose) and at Day 1: 3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis

  35. Change From Baseline Values for Pulse Rate

    Pulse rate was measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1, predose) and at Day 1: 3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis

07

Results

Posted Jun 3, 2021

Participant flow

This was a randomized, open label study that evaluated the effect of daprodustat on blood pressure in participants with anemia associated with chronic kidney disease on hemodialysis switched from a stable dose of an erythropoiesis-stimulating agent.

Acute Challenge 1 (Day 1)
Participant flow — Acute Challenge 1 (Day 1)
MilestoneDaprodustatRecombinant Human Erythropoietin
Started4543
Completed4543
Not completed00
Hgb Maintenance Phase (8 Weeks)
Participant flow — Hgb Maintenance Phase (8 Weeks)
MilestoneDaprodustatRecombinant Human Erythropoietin
Started4543
Completed3236
Not completed137
Withdrew: Withdrawal by subject30
Withdrew: Physician decision11
Withdrew: Protocol-specified withdrawal criterion74
Withdrew: Adverse event22
Acute Challenge 2 (Day 57)
Participant flow — Acute Challenge 2 (Day 57)
MilestoneDaprodustatRecombinant Human Erythropoietin
Started3236
Completed3236
Not completed00
Follow-up Period (14 Days)
Participant flow — Follow-up Period (14 Days)
MilestoneDaprodustatRecombinant Human Erythropoietin
Started3236
Completed3236
Not completed00

Outcome measures

PrimaryAverage of Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM) Over 6-hour Post Dosing on Day 57

The effect of daprodustat and epoetin alfa on blood pressure was compared using ABPM after 8 weeks of Hgb maintenace therapy on Day 57. Analysis was based on "analysis of covariance (ANCOVA) with terms for treatment, prior erythropoiesis-stimulating agent (ESA) dose (low/high), post-Hemodialysis dependent (HD)/pre-AC 1 SBP, difference between post-HD/pre-AC 2 SBP and post-HD/pre-AC 1 SBP and treatment by difference in post-HD SBP between AC 1 and 2 interaction." Least square (LS) mean of 6 hour average SBP post AC2 on Day 57 and its corresponding standard error has been presented.

Time frame:
Up to 6 hours post dose on Day 57
Reported as:
Least squares mean · Millimeters of mercury (mmHg)
Average of Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM) Over 6-hour Post Dosing on Day 57
Millimeters of mercury (mmHg)DaprodustatRecombinant Human Erythropoietin
Average of Systolic Blood Pressure (SBP) Measured by Ambulatory Blood Pressure Monitoring (ABPM) Over 6-hour Post Dosing on Day 57142.87 ± 3.039143.03 ± 2.995
Statistical analysis
  • Daprodustat vs Recombinant Human Erythropoietin · ANCOVA · p = 0.9694 (p-value for the difference between treatment groups were presented from ANCOVA model for the superiority assessment.) · Ls mean difference: -0.17 · 95% CI -8.80 to 8.47LS Mean treatment difference (daprodustat minus recombinant human erythropoietin) and its corresponding 95% confidence interval (CI) has been presented.
SecondaryAverage of SBP, Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) Measured by ABPM Over 6-hour Post Dosing on Day 1

The initial effect of daprodustat and epoetin alfa on blood pressure was compared using ABPM over 6 hour post-dosing on Day 1. Analysis was based on ANCOVA with terms for treatment, prior ESA dose (low/high), post-HD/pre-AC1 SBP, DBP and MAP. LS mean of 6 hour average SBP, DBP and MAP post AC1 on Day 1 and its corresponding standard error has been presented.

Time frame:
Up to 6 hours post dose on Day 1
Reported as:
Least squares mean · mmHg
Average of SBP, Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) Measured by ABPM Over 6-hour Post Dosing on Day 1
mmHgDaprodustatRecombinant Human Erythropoietin
SBP141.36 ± 3.115142.68 ± 3.313
DBP75.97 ± 1.25377.92 ± 1.332
MAP99.18 ± 2.212101.58 ± 2.351
Statistical analysis
  • Daprodustat vs Recombinant Human Erythropoietin · ANCOVA · p = 0.7745 (p-value for the difference between treatment groups was presented from ANCOVA model for the superiority assessment.) · Ls mean difference: -1.32 · 95% CI -10.46 to 7.83LS Mean treatment difference (daprodustat minus recombinant human erythropoietin) of SBP and its corresponding 95% CI has been presented.
  • Daprodustat vs Recombinant Human Erythropoietin · ANCOVA · p = 0.2910 (p-value for the difference between treatment groups was presented from ANCOVA model for the superiority assessment.) · Ls mean difference: -1.95 · 95% CI -5.62 to 1.71LS Mean treatment difference (daprodustat minus recombinant human erythropoietin) of DBP and its corresponding 95% CI has been presented.
  • Daprodustat vs Recombinant Human Erythropoietin · ANCOVA · p = 0.4611 (p-value for the difference between treatment groups was presented from ANCOVA model for the superiority assessment.) · Ls mean difference: -2.40 · 95% CI -8.88 to 4.07LS Mean treatment difference (daprodustat minus recombinant human erythropoietin) of MAP and its corresponding 95% CI has been presented.
SecondaryAverage of Heart Rate (HR) Measured by ABPM Over 6 Hour Post Dosing on Day 1

The initial effect of daprodustat and epoetin alfa on HR was compared using ABPM over 6 hour post-dosing on Day 1. Analysis was based on ANCOVA with terms for treatment, prior ESA dose (low/high), post-HD/pre-AC1 HR. LS mean of 6 hour average HR post AC1 on Day 1 and its corresponding standard error has been presented.

Time frame:
Up to 6 hours post dose on Day 1
Reported as:
Least squares mean · Beats per minute
Average of Heart Rate (HR) Measured by ABPM Over 6 Hour Post Dosing on Day 1
Beats per minuteDaprodustatRecombinant Human Erythropoietin
Average of Heart Rate (HR) Measured by ABPM Over 6 Hour Post Dosing on Day 170.77 ± 1.41673.72 ± 1.507
Statistical analysis
  • Daprodustat vs Recombinant Human Erythropoietin · ANCOVA · p = 0.1648 (p-value for the difference between treatment groups was presented from ANCOVA model for the superiority assessment.) · Ls mean difference: -2.95 · 95% CI -7.14 to 1.24LS Mean treatment difference (daprodustat minus recombinant human erythropoietin) and its corresponding 95% CI has been presented.
SecondaryArea Under the Effect Curve (AUEC) of SBP, DBP and MAP Measured by ABPM Over 24-hour Post Dosing on Day 1

The initial effect of daprodustat and epoetin alfa on blood pressure was compared using AUEC of SBP, DBP and MAP measured by ABPM over 24-hour post dosing on Day 1. Analysis was based on ANCOVA with terms for treatment and prior ESA dose (low/high). LS mean of AUEC up to 24 hours post dose on Day 1 and its corresponding standard error has been presented.

Time frame:
Up to 24 hours post dose on Day 1
Reported as:
Least squares mean · mmHg*Hours
Area Under the Effect Curve (AUEC) of SBP, DBP and MAP Measured by ABPM Over 24-hour Post Dosing on Day 1
mmHg*HoursDaprodustatRecombinant Human Erythropoietin
AUEC of SBP3337.91 ± 84.1443351.33 ± 90.217
AUEC of DBP1763.11 ± 39.8141834.82 ± 42.688
AUEC of MAP2324.69 ± 57.5172378.93 ± 61.668
Statistical analysis
  • Daprodustat vs Recombinant Human Erythropoietin · ANCOVA · p = 0.9142 (p-value for the difference between treatment groups was presented from ANCOVA model for the superiority assessment.) · Ls mean difference: -13.42 · 95% CI -261.75 to 234.92LS Mean treatment difference (daprodustat minus recombinant human erythropoietin) for AUEC of SBP and its corresponding 95% CI has been presented.
  • Daprodustat vs Recombinant Human Erythropoietin · ANCOVA · p = 0.2266 (p-value for the difference between treatment groups was presented from ANCOVA model for the superiority assessment.) · Ls mean difference: -71.70 · 95% CI -189.21 to 45.80LS Mean treatment difference (daprodustat minus recombinant human erythropoietin) for AUEC of DBP and its corresponding 95% CI has been presented.
  • Daprodustat vs Recombinant Human Erythropoietin · ANCOVA · p = 0.5246 (p-value for the difference between treatment groups was presented from ANCOVA model for the superiority assessment.) · Ls mean difference: -54.24 · 95% CI -223.99 to 115.51LS Mean treatment difference (daprodustat minus recombinant human erythropoietin) for AUEC of MAP and its corresponding 95% CI has been presented.
SecondaryAUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 1

The initial effect of daprodustat and epoetin alfa on HR was compared using AUEC of HR measured by ABPM over 24-hour post dosing. Analysis was based on ANCOVA with terms for treatment and prior ESA dose (low/high). LS mean of AUEC up to 24 hours post dose on Day 1 and its corresponding standard error has been presented.

Time frame:
Up to 24 hours post dose on Day 1
Reported as:
Least squares mean · Beats per minute*Hours
AUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 1
Beats per minute*HoursDaprodustatRecombinant Human Erythropoietin
AUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 11652.63 ± 35.1521727.03 ± 37.690
Statistical analysis
  • Daprodustat vs Recombinant Human Erythropoietin · ANCOVA · p = 0.1563 (p-value for the difference between treatment groups was presented from ANCOVA model for the superiority assessment.) · Ls mean difference: -74.40 · 95% CI -178.15 to 29.34LS Mean treatment difference (daprodustat minus recombinant human erythropoietin) for AUEC of HR and its corresponding 95% CI has been presented.
SecondaryAverage of DBP and MAP Measured by ABPM Over 6-hour Post Dosing on Day 57

The effect of daprodustat and epoetin alfa on blood pressure was compared using ABPM over 6 hour post-dosing after AC2 on Day 57. Analysis was based on ANCOVA with terms for treatment, prior ESA dose (low/high), post-HD/pre-AC1 DBP and MAP, difference between post-HD/pre-AC2 DBP and MAP and post-HD/pre-AC1 DBP and MAP and treatment by difference in post-HD DBP and MAP between AC1 and 2 interaction. LS mean of 6 hour average DBP and MAP post AC2 on Day 57 and its corresponding standard error has been presented.

Time frame:
Up to 6 hours post dose on Day 57
Reported as:
Least squares mean · mmHg
Average of DBP and MAP Measured by ABPM Over 6-hour Post Dosing on Day 57
mmHgDaprodustatRecombinant Human Erythropoietin
DBP75.58 ± 1.46577.64 ± 1.436
MAP98.98 ± 2.208101.49 ± 2.169
Statistical analysis
  • Daprodustat vs Recombinant Human Erythropoietin · ANCOVA · p = 0.3247 (p-value for the difference between treatment groups was presented from ANCOVA model for the superiority assessment.) · Ls mean difference: -2.06 · 95% CI -6.23 to 2.10LS Mean treatment difference (daprodustat minus recombinant human erythropoietin) of DBP and its corresponding 95% CI has been presented.
  • Daprodustat vs Recombinant Human Erythropoietin · ANCOVA · p = 0.4235 (p-value for the difference between treatment groups was presented from ANCOVA model for the superiority assessment.) · Ls mean difference: -2.51 · 95% CI -8.76 to 3.74LS Mean treatment difference (daprodustat minus recombinant human erythropoietin) of MAP and its corresponding 95% CI has been presented.
SecondaryAverage of HR Measured by ABPM Over 6 Hour Post Dosing on Day 57

The effect of daprodustat and epoetin alfa on HR was compared using ABPM over 6 hour post-dosing. Analysis was based on ANCOVA with terms for treatment, prior ESA dose (low/high), post-HD/pre-AC1 HR, difference between post-HD/pre-AC2 HR and post-HD/pre-AC1 HR and treatment by difference in post-HD HR between AC1 and 2 interaction. LS mean of 6 hour average HR post AC2 on Day 57 and its corresponding standard error has been presented.

Time frame:
Up to 6 hours post dose on Day 57
Reported as:
Least squares mean · Beats per minute
Average of HR Measured by ABPM Over 6 Hour Post Dosing on Day 57
Beats per minuteDaprodustatRecombinant Human Erythropoietin
Average of HR Measured by ABPM Over 6 Hour Post Dosing on Day 5770.49 ± 1.14670.62 ± 1.125
Statistical analysis
  • Daprodustat vs Recombinant Human Erythropoietin · ANCOVA · p = 0.9353 (p-value for the difference between treatment groups was presented from ANCOVA model for the superiority assessment.) · Ls mean difference: -0.13 · 95% CI -3.41 to 3.14LS Mean treatment difference (daprodustat minus recombinant human erythropoietin) and its corresponding 95% CI has been presented.
SecondaryAUEC of SBP, DBP and MAP Measured by ABPM Over 24-hour Post Dosing on Day 57

The effect of daprodustat and epoetin alfa on blood pressure was compared using AUEC of SBP, DBP and MAP measured by ABPM over 24-hour post dosing on Day 57. Analysis was based on ANCOVA with terms for treatment and prior ESA dose (low/high). LS mean of AUEC up to 24 hour post dose on Day 57 and its corresponding standard error has been presented.

Time frame:
Up to 24 hours post dose on Day 57
Reported as:
Least squares mean · mmHg*Hours
AUEC of SBP, DBP and MAP Measured by ABPM Over 24-hour Post Dosing on Day 57
mmHg*HoursDaprodustatRecombinant Human Erythropoietin
AUEC of SBP3288.43 ± 85.8053433.40 ± 91.786
AUEC of DBP1736.11 ± 38.6591853.60 ± 41.354
AUEC of MAP2299.42 ± 58.7122431.36 ± 62.804
Statistical analysis
  • Daprodustat vs Recombinant Human Erythropoietin · ANCOVA · p = 0.2573 (p-value for the difference between treatment groups was presented from ANCOVA model for the superiority assessment.) · Ls mean difference: -144.97 · 95% CI -399.71 to 109.76LS Mean treatment difference (daprodustat minus recombinant human erythropoietin) for AUEC of SBP and its corresponding 95% CI has been presented.
  • Daprodustat vs Recombinant Human Erythropoietin · ANCOVA · p = 0.0450 (p-value for the difference between treatment groups was presented from ANCOVA model for the superiority assessment.) · Ls mean difference: -117.49 · 95% CI -232.26 to -2.72LS Mean treatment difference (daprodustat minus recombinant human erythropoietin) for AUEC of DBP and its corresponding 95% CI has been presented.
  • Daprodustat vs Recombinant Human Erythropoietin · ANCOVA · p = 0.1341 (p-value for the difference between treatment groups was presented from ANCOVA model for the superiority assessment.) · Ls mean difference: -131.94 · 95% CI -306.24 to 42.36LS Mean treatment difference (daprodustat minus recombinant human erythropoietin) for AUEC of MAP and its corresponding 95% CI has been presented.
SecondaryAUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 57

The effect of daprodustat and epoetin alfa on HR was compared using AUEC of HR measured by ABPM over 24-hour post dosing on Day 57. Analysis was based on ANCOVA with terms for treatment and prior ESA dose (low/high). LS mean of AUEC up to 24 hour post dose on Day 57 and its corresponding standard error has been presented.

Time frame:
Up to 24 hours post dose on Day 57
Reported as:
Least squares mean · Beats per minute*Hours
AUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 57
Beats per minute*HoursDaprodustatRecombinant Human Erythropoietin
AUEC of HR Measured by ABPM Over 24-hour Post Dosing on Day 571579.38 ± 40.8861677.06 ± 43.736
Statistical analysis
  • Daprodustat vs Recombinant Human Erythropoietin · ANCOVA · p = 0.1119 (p-value for the difference between treatment groups was presented from ANCOVA model for the superiority assessment.) · Ls mean difference: -97.67 · 95% CI -219.05 to 23.71LS Mean treatment difference (daprodustat minus recombinant human erythropoietin) for AUEC of HR and its corresponding 95% CI has been presented.
SecondaryChange From Pre-dose in SBP, DBP and MAP at Day 1

The change from pre-dose in SBP, DBP and MAP was measured using ABPM to compare the initial effect of daprodustat to epoetin alfa after AC1 on Day 1. Change from pre-dose at each timepoint is calculated as measurement at post-dose minus pre-acute challenge 1 measurement.

Time frame:
Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24 hours post-dose
Reported as:
Mean · mmHg
Change From Pre-dose in SBP, DBP and MAP at Day 1
mmHgDaprodustatRecombinant Human Erythropoietin
SBP, Hour 1, n=34, 311.00 ± 17.1785.27 ± 20.471
SBP, Hour 2, n=35, 31-4.99 ± 28.1704.72 ± 22.651
SBP, Hour 3, n=35, 31-5.85 ± 29.6365.09 ± 21.163
SBP, Hour 4, n=35, 31-1.68 ± 26.0000.93 ± 23.962
SBP, Hour 5, n=35, 31-1.86 ± 29.171-2.10 ± 23.849
SBP, Hour 6, n=35, 310.29 ± 31.903-2.54 ± 28.908
SBP, Hour 7, n=34, 262.30 ± 33.8960.63 ± 19.016
SBP, Hour 8, n=33, 290.43 ± 31.4183.83 ± 20.723
SBP, Hour 9, n=33, 30-5.81 ± 30.7250.25 ± 26.294
SBP, Hour 10, n=31, 28-5.70 ± 28.0181.48 ± 25.952
SBP, Hour 11, n=33, 27-7.00 ± 27.5291.96 ± 24.421
SBP, Hour 12, n=35, 28-6.05 ± 29.932-1.67 ± 19.380
SBP, Hour 13, n=34, 28-2.49 ± 25.319-1.37 ± 25.596
SBP, Hour 14, n=34, 31-5.30 ± 30.0304.57 ± 29.767
SBP, Hour 15, n=32, 26-1.47 ± 33.573-0.13 ± 24.287
SBP, Hour 16, n=34, 31-4.40 ± 30.9908.59 ± 24.729
SBP, Hour 17, n=32, 30-5.05 ± 29.7951.76 ± 23.896
SBP, Hour 18, n=32, 27-5.23 ± 25.9935.48 ± 23.330
SBP, Hour 19, n=34, 27-3.01 ± 24.2301.52 ± 21.072
SBP, Hour 20, n=33, 27-13.27 ± 24.1386.89 ± 16.834
SBP, Hour 21, n=30, 27-8.32 ± 26.0031.72 ± 26.777
SBP, Hour 22, n=29, 27-3.93 ± 26.1063.50 ± 24.428
SBP, Hour 23, n=31, 262.73 ± 28.3438.72 ± 24.868
SBP, Hour 24, n=31, 272.63 ± 29.3795.02 ± 26.601
DBP, Hour 1, n=34, 310.01 ± 9.3170.99 ± 13.110
DBP, Hour 2, n=35, 31-0.82 ± 15.3991.97 ± 11.986
DBP, Hour 3, n=35, 31-1.30 ± 14.6600.88 ± 11.858
DBP, Hour 4, n=35, 31-1.06 ± 14.552-1.17 ± 13.621
DBP, Hour 5, n=35, 31-0.69 ± 16.618-1.49 ± 11.684
DBP, Hour 6, n=35, 31-0.06 ± 14.799-1.49 ± 14.457
DBP, Hour 7, n=34, 26-0.12 ± 16.324-1.27 ± 15.272
DBP, Hour 8, n=33, 291.35 ± 15.9001.79 ± 15.178
DBP, Hour 9, n=33, 30-2.14 ± 15.188-0.68 ± 11.874
DBP, Hour 10, n=31, 28-3.52 ± 14.246-0.82 ± 12.802
DBP, Hour 11, n=33, 27-4.88 ± 14.691-2.45 ± 10.987
DBP, Hour 12, n=35, 28-4.79 ± 14.561-3.95 ± 10.718
DBP, Hour 13, n=34, 28-2.15 ± 15.185-2.65 ± 12.841
DBP, Hour 14, n=34, 31-3.99 ± 14.153-1.00 ± 14.759
DBP, Hour 15, n=32, 26-0.54 ± 19.203-4.12 ± 13.905
DBP, Hour 16, n=34, 31-3.56 ± 15.6151.15 ± 14.186
DBP, Hour 17, n=32, 30-3.65 ± 14.949-2.98 ± 13.732
DBP, Hour 18, n=32, 27-2.08 ± 17.0150.30 ± 14.219
DBP, Hour 19, n=34, 27-0.36 ± 19.650-0.43 ± 14.965
DBP, Hour 20, n=33, 27-2.96 ± 15.5790.40 ± 14.501
DBP, Hour 21, n=30, 27-2.54 ± 15.2461.90 ± 15.507
DBP, Hour 22, n=29, 27-0.25 ± 15.037-1.96 ± 12.058
DBP, Hour 23, n=31, 264.05 ± 19.055-0.44 ± 13.218
DBP, Hour 24, n=31, 274.48 ± 18.0972.16 ± 15.124
MAP, Hour 1, n=34, 31-1.87 ± 15.2522.83 ± 19.439
MAP, Hour 2, n=35, 31-4.79 ± 24.7424.20 ± 17.890
MAP, Hour 3, n=35, 31-5.13 ± 22.3423.46 ± 14.940
MAP, Hour 4, n=35, 31-4.78 ± 23.640-1.05 ± 17.552
MAP, Hour 5, n=35, 31-3.48 ± 26.458-1.18 ± 16.235
MAP, Hour 6, n=35, 31-1.27 ± 25.359-2.17 ± 19.573
MAP, Hour 7, n=34, 260.45 ± 28.4450.87 ± 18.659
MAP, Hour 8, n=33, 290.08 ± 27.4872.20 ± 17.002
MAP, Hour 9, n=33, 30-7.02 ± 24.4980.61 ± 17.072
MAP, Hour 10, n=31, 28-8.18 ± 24.0570.76 ± 18.604
MAP, Hour 11, n=33, 27-8.74 ± 25.719-3.60 ± 19.022
MAP, Hour 12, n=35, 28-6.49 ± 26.669-6.15 ± 16.336
MAP, Hour 13, n=34, 28-5.72 ± 23.609-3.32 ± 17.660
MAP, Hour 14, n=34, 31-6.99 ± 25.710-0.75 ± 17.024
MAP, Hour 15, n=32, 26-4.06 ± 27.693-5.10 ± 19.458
MAP, Hour 16, n=34, 31-4.79 ± 26.8053.84 ± 22.886
MAP, Hour 17, n=32, 30-5.10 ± 25.873-2.09 ± 19.856
MAP, Hour 18, n=32, 27-6.98 ± 24.7901.52 ± 18.745
MAP, Hour 19, n=34, 27-4.44 ± 26.186-1.02 ± 17.275
MAP, Hour 20, n=33, 27-9.47 ± 23.1864.23 ± 16.311
MAP, Hour 21, n=30, 27-7.39 ± 22.6113.87 ± 20.860
MAP, Hour 22, n=29, 27-2.77 ± 21.9380.75 ± 16.888
MAP, Hour 23, n=31, 260.88 ± 27.3814.10 ± 18.818
MAP, Hour 24, n=31, 272.02 ± 26.2532.20 ± 19.276
SecondaryChange From Pre-dose in HR at Day 1

The change from pre-dose in HR was measured using ABPM to compare the initial effect of daprodustat to epoetin alfa after AC1 on Day 1. Change from pre-dose at each timepoint is calculated as measurement at post-dose minus pre-acute challenge 1 measurement.

Time frame:
Day 1: Pre-dose and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24 hours post-dose
Reported as:
Mean · Beats per minute
Change From Pre-dose in HR at Day 1
Beats per minuteDaprodustatRecombinant Human Erythropoietin
Hour 1, n=34, 31-1.16 ± 9.2830.13 ± 15.465
Hour 2, n=35, 31-1.05 ± 17.259-2.06 ± 15.409
Hour 3, n=35, 310.76 ± 15.920-0.16 ± 14.911
Hour 4, n=35, 313.18 ± 12.717-1.13 ± 17.798
Hour 5, n=35, 310.91 ± 13.782-0.66 ± 14.119
Hour 6, n=35, 310.97 ± 14.763-1.66 ± 13.023
Hour 7, n=34, 262.14 ± 13.620-1.01 ± 11.592
Hour 8, n=33, 290.62 ± 13.326-1.11 ± 18.376
Hour 9, n=33, 300.20 ± 14.5330.67 ± 15.411
Hour 10, n=31, 282.54 ± 13.5751.60 ± 13.612
Hour 11, n=33, 272.07 ± 14.2471.57 ± 14.132
Hour 12, n=35, 280.77 ± 12.386-2.01 ± 14.767
Hour 13, n=34, 28-0.25 ± 12.895-2.45 ± 14.861
Hour 14, n=34, 31-1.54 ± 13.1480.25 ± 13.020
Hour 15, n=32, 26-0.92 ± 13.406-3.06 ± 13.156
Hour 16, n=34, 31-1.02 ± 14.018-2.87 ± 11.762
Hour 17, n=32, 30-0.85 ± 14.631-4.34 ± 13.284
Hour 18, n=32, 270.60 ± 15.5530.98 ± 11.443
Hour 19, n=34, 27-0.56 ± 14.407-2.65 ± 13.220
Hour 20, n=33, 27-1.91 ± 13.956-4.77 ± 17.083
Hour 21, n=30, 27-1.82 ± 13.841-3.00 ± 13.342
Hour 22, n=29, 270.82 ± 11.686-2.61 ± 13.292
Hour 23, n=31, 26-1.01 ± 12.6970.24 ± 13.148
Hour 24, n=31, 27-0.89 ± 17.530-0.96 ± 14.651
SecondaryPlasma Concentrations of Daprodustat

Blood samples were collected at indicated time points for the concentrations of daprodustat.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Reported as:
Mean · Nanograms per milliliter
Plasma Concentrations of Daprodustat
Nanograms per milliliterDaprodustat
Day 1, Predose, n=450.000 ± 0.000
Day 1, 0.5 hours, n=43197.118 ± 329.0251
Day 1, 1 hour, n=43265.828 ± 340.7690
Day 1, 2 hours, n=43156.103 ± 150.4148
Day 1, 3 hours, n=43114.485 ± 139.8114
Day 1, 4 hours, n=44105.375 ± 150.0982
Day 1, 6 hours, n=4471.995 ± 104.2462
Day 1, 8 hours, n=4350.069 ± 91.2574
Day 1, 12 hours, n=4114.165 ± 30.2719
Day 1, 16 hours, n=435.350 ± 11.0233
Day 1, 24 hours, n=432.899 ± 10.8052
Day 57, Predose, n=318.657 ± 21.3825
Day 57, 0.5 hours, n=31175.616 ± 257.3578
Day 57, 1 hour, n=31260.817 ± 307.2242
Day 57, 2 hours, n=30245.277 ± 251.2676
Day 57, 3 hours, n=31142.366 ± 154.9041
Day 57, 4 hours, n=3282.696 ± 104.8654
Day 57, 6 hours, n=3143.751 ± 55.8532
Day 57, 8 hours, n=3116.484 ± 27.2733
Day 57, 12 hours, n=308.661 ± 16.8915
Day 57, 16 hours, n=307.279 ± 21.2784
Day 57, 24 hours, n=311.371 ± 2.0177
SecondaryPlasma Concentrations of Metabolite GSK2391220

Blood samples were collected at indicated time points for the concentrations of metabolite GSK2391220.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Reported as:
Mean · Nanograms per milliliter
Plasma Concentrations of Metabolite GSK2391220
Nanograms per milliliterDaprodustat
Day 1, Predose, n=450.000 ± 0.000
Day 1, 0.5 hours, n=439.847 ± NA
Day 1, 1 hour, n=4314.361 ± 21.6405
Day 1, 2 hours, n=4330.036 ± 29.6152
Day 1, 3 hours, n=4432.359 ± 28.6734
Day 1, 4 hours, n=4332.892 ± 27.2772
Day 1, 6 hours, n=4333.105 ± 20.9136
Day 1, 8 hours, n=4232.267 ± 16.3824
Day 1, 12 hours, n=4023.921 ± 15.1007
Day 1, 16 hours, n=4219.771 ± 13.5013
Day 1, 24 hours, n=4212.693 ± 10.1135
Day 57, Predose, n=313.019 ± 4.2327
Day 57, 0.5 hours, n=3110.043 ± 12.5832
Day 57, 1 hour, n=3112.410 ± 13.3576
Day 57, 2 hours, n=3023.433 ± 21.4154
Day 57, 3 hours, n=3132.861 ± 26.3829
Day 57, 4 hours, n=3238.443 ± 27.9354
Day 57, 6 hours, n=3141.432 ± 24.2976
Day 57, 8 hours, n=3133.689 ± 20.3669
Day 57, 12 hours, n=3125.771 ± 17.8554
Day 57, 16 hours, n=3121.481 ± 15.6404
Day 57, 24 hours, n=3214.836 ± 11.2824
SecondaryPlasma Concentrations of Metabolite GSK2506104

Blood samples were collected at indicated time points for the concentrations of metabolite GSK2506104.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Reported as:
Mean · Nanograms per milliliter
Plasma Concentrations of Metabolite GSK2506104
Nanograms per milliliterDaprodustat
Day 1, Predose, n=450.000 ± 0.000
Day 1, 0.5 hours, n=439.337 ± NA
Day 1, 1 hour, n=4313.263 ± 20.5510
Day 1, 2 hours, n=4328.986 ± 28.4324
Day 1, 3 hours, n=4432.623 ± 29.1622
Day 1, 4 hours, n=4334.266 ± 27.5021
Day 1, 6 hours, n=4337.250 ± 21.9404
Day 1, 8 hours, n=4239.463 ± 17.2013
Day 1, 12 hours, n=4033.822 ± 16.6962
Day 1, 16 hours, n=4231.224 ± 16.3048
Day 1, 24 hours, n=4224.268 ± 14.2298
Day 57, Predose, n=314.133 ± 4.5315
Day 57, 0.5 hours, n=3110.759 ± 11.6369
Day 57, 1 hour, n=3112.902 ± 12.5068
Day 57, 2 hours, n=3023.391 ± 20.1627
Day 57, 3 hours, n=3133.561 ± 26.4516
Day 57, 4 hours, n=3241.089 ± 28.8815
Day 57, 6 hours, n=3147.511 ± 25.5686
Day 57, 8 hours, n=3143.646 ± 22.0075
Day 57, 12 hours, n=3139.685 ± 23.4732
Day 57, 16 hours, n=3136.234 ± 22.1830
Day 57, 24 hours, n=3227.808 ± 14.8739
SecondaryPlasma Concentrations of Metabolite GSK2487818

Blood samples were collected at indicated time points for the concentrations of metabolite GSK2487818.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Reported as:
Mean · Nanograms per milliliter
Plasma Concentrations of Metabolite GSK2487818
Nanograms per milliliterDaprodustat
Day 1, Predose, n=450.000 ± 0.000
Day 1, 0.5 hours, n=438.624 ± NA
Day 1, 1 hour, n=4313.181 ± 19.2280
Day 1, 2 hours, n=4325.204 ± 24.8233
Day 1, 3 hours, n=4423.632 ± 21.0661
Day 1, 4 hours, n=4320.726 ± 17.9713
Day 1, 6 hours, n=4315.509 ± 10.4545
Day 1, 8 hours, n=4211.654 ± 9.1747
Day 1, 12 hours, n=395.673 ± 6.4670
Day 1, 16 hours, n=433.298 ± 4.6779
Day 1, 24 hours, n=431.379 ± 2.1969
Day 57, Predose, n=311.503 ± NA
Day 57, 0.5 hours, n=317.760 ± 12.2768
Day 57, 1 hour, n=3110.507 ± 13.6474
Day 57, 2 hours, n=3020.254 ± 20.1125
Day 57, 3 hours, n=3025.092 ± 20.7688
Day 57, 4 hours, n=3224.865 ± 18.7941
Day 57, 6 hours, n=3121.749 ± 16.6572
Day 57, 8 hours, n=3111.419 ± 11.2821
Day 57, 12 hours, n=315.537 ± 9.1160
Day 57, 16 hours, n=303.613 ± 6.4974
Day 57, 24 hours, n=311.693 ± 2.9455
SecondaryPlasma Concentrations of Metabolite GSK2506102

Blood samples were collected at indicated time points for the concentrations of metabolite GSK25206102.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Reported as:
Mean · Nanograms per milliliter
Plasma Concentrations of Metabolite GSK2506102
Nanograms per milliliterDaprodustat
Day 1, Predose, n=450.000 ± 0.000
Day 1, 0.5 hours, n=431.862 ± NA
Day 1, 1 hour, n=442.575 ± NA
Day 1, 2 hours, n=435.999 ± 5.9281
Day 1, 3 hours, n=447.047 ± 6.3772
Day 1, 4 hours, n=437.554 ± 6.0767
Day 1, 6 hours, n=438.564 ± 5.0888
Day 1, 8 hours, n=429.379 ± 3.9554
Day 1, 12 hours, n=408.658 ± 3.6930
Day 1, 16 hours, n=428.225 ± 3.7400
Day 1, 24 hours, n=427.024 ± 3.5347
Day 57, Predose, n=311.126 ± 1.0181
Day 57, 0.5 hours, n=302.472 ± 2.2298
Day 57, 1 hour, n=312.890 ± 2.4847
Day 57, 2 hours, n=305.082 ± 4.1937
Day 57, 3 hours, n=317.688 ± 5.7677
Day 57, 4 hours, n=329.474 ± 6.3929
Day 57, 6 hours, n=3011.507 ± 5.3600
Day 57, 8 hours, n=3110.945 ± 4.9425
Day 57, 12 hours, n=3110.286 ± 5.1703
Day 57, 16 hours, n=319.735 ± 5.1306
Day 57, 24 hours, n=328.449 ± 3.7371
SecondaryPlasma Concentrations of Metabolite GSK2531398

Blood samples were collected at indicated time points for the concentrations of metabolite GSK2531398.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Reported as:
Mean · Nanograms per milliliter
Plasma Concentrations of Metabolite GSK2531398
Nanograms per milliliterDaprodustat
Day 1, Predose, n=450.000 ± 0.000
Day 1, 0.5 hours, n=434.409 ± NA
Day 1, 1 hour, n=446.139 ± NA
Day 1, 2 hours, n=4313.779 ± 13.5109
Day 1, 3 hours, n=4415.087 ± 13.4427
Day 1, 4 hours, n=4314.881 ± 12.5678
Day 1, 6 hours, n=4314.907 ± 9.6957
Day 1, 8 hours, n=4213.930 ± 7.4098
Day 1, 12 hours, n=409.784 ± 6.6328
Day 1, 16 hours, n=427.751 ± 5.9158
Day 1, 24 hours, n=424.687 ± 4.1099
Day 57, Predose, n=311.246 ± 1.9695
Day 57, 0.5 hours, n=304.482 ± 5.7104
Day 57, 1 hour, n=315.406 ± 5.8321
Day 57, 2 hours, n=3010.580 ± 10.1185
Day 57, 3 hours, n=3115.191 ± 12.9991
Day 57, 4 hours, n=3217.904 ± 13.4024
Day 57, 6 hours, n=3019.827 ± 11.4600
Day 57, 8 hours, n=3115.038 ± 11.0475
Day 57, 12 hours, n=3110.292 ± 8.2309
Day 57, 16 hours, n=318.348 ± 7.1590
Day 57, 24 hours, n=325.334 ± 4.8807
SecondaryPlasma Concentrations of Metabolite GSK2531401

Blood samples were collected at indicated time points for the concentrations of metabolite GSK2531401.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Reported as:
Mean · Nanograms per milliliter
Plasma Concentrations of Metabolite GSK2531401
Nanograms per milliliterDaprodustat
Day 1, Predose, n=450.000 ± 0.000
Day 1, 0.5 hours, n=432.927 ± NA
Day 1, 1 hour, n=444.134 ± NA
Day 1, 2 hours, n=4311.013 ± 11.9279
Day 1, 3 hours, n=4413.752 ± 14.0238
Day 1, 4 hours, n=4315.497 ± 14.6142
Day 1, 6 hours, n=4318.302 ± 13.9244
Day 1, 8 hours, n=4221.139 ± 13.2221
Day 1, 12 hours, n=4020.174 ± 11.6828
Day 1, 16 hours, n=4220.127 ± 12.1374
Day 1, 24 hours, n=4218.143 ± 11.6065
Day 57, Predose, n=312.448 ± 2.0199
Day 57, 0.5 hours, n=314.486 ± 3.9244
Day 57, 1 hour, n=315.480 ± 5.0425
Day 57, 2 hours, n=309.015 ± 8.4201
Day 57, 3 hours, n=3114.027 ± 12.7046
Day 57, 4 hours, n=3217.722 ± 14.2802
Day 57, 6 hours, n=3024.285 ± 15.7868
Day 57, 8 hours, n=3125.557 ± 16.2248
Day 57, 12 hours, n=3125.288 ± 15.7597
Day 57, 16 hours, n=3124.881 ± 15.3688
Day 57, 24 hours, n=3221.914 ± 12.9806
SecondaryMaximum Plasma Concentration (Cmax) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401

Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat and its metabolites GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401. PK parameters were analyzed using standard non-compartmental analysis.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Reported as:
Geometric mean · Nanograms per milliliter
Maximum Plasma Concentration (Cmax) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401
Nanograms per milliliterDaprodustat
Daprodustat, Day 1, n=44218.841 ± 187.869
Daprodustat, Day 57, n=32163.795 ± 330.249
GSK2391220, Day 1, n=4439.506 ± 66.816
GSK2391220, Day 57, n=3244.703 ± 57.029
GSK2487818, Day 1, n=4426.678 ± 79.992
GSK2487818, Day 57, n=3224.846 ± 117.570
GSK2506102, Day 1, n=449.933 ± 62.188
GSK2506102, Day 57, n=3212.114 ± 46.563
GSK2506104, Day 1, n=4443.169 ± 61.558
GSK2506104, Day 57, n=3251.643 ± 48.087
GSK2531398, Day 1, n=4418.454 ± 67.277
GSK2531398, Day 57, n=3220.362 ± 67.040
GSK2531401, Day 1, n=4418.335 ± 96.906
GSK2531401, Day 57, n=3223.337 ± 75.801
SecondaryTime of Occurrence of Cmax (Tmax) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401

Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat and its metabolites GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401. PK parameters were analyzed using standard non-compartmental analysis.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Reported as:
Median · Hours
Time of Occurrence of Cmax (Tmax) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401
HoursDaprodustat
Daprodustat, Day 1, n=442.000 (0.38 to 8.00)
Daprodustat, Day 57, n=322.000 (0.50 to 12.00)
GSK2391220, Day 1, n=444.160 (0.50 to 16.00)
GSK2391220, Day 57, n=324.000 (0.50 to 16.00)
GSK2487818, Day 1, n=443.090 (0.50 to 12.00)
GSK2487818, Day 57, n=324.000 (0.50 to 12.00)
GSK2506102, Day 1, n=446.000 (0.50 to 24.00)
GSK2506102, Day 57, n=326.000 (2.00 to 24.00)
GSK2506104, Day 1, n=446.000 (0.50 to 16.30)
GSK2506104, Day 57, n=325.990 (0.50 to 24.00)
GSK2531398, Day 1, n=444.160 (0.50 to 24.00)
GSK2531398, Day 57, n=324.000 (0.50 to 16.00)
GSK2531401, Day 1, n=448.015 (1.00 to 24.50)
GSK2531401, Day 57, n=328.000 (3.00 to 24.00)
SecondaryTerminal Phase Half-life (t1/2) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401

Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat and its metabolites GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401. PK parameters were analyzed using standard non-compartmental analysis.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Reported as:
Geometric mean · Hours
Terminal Phase Half-life (t1/2) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401
HoursDaprodustat
Daprodustat, Day 1, n=223.031 ± 40.320
Daprodustat, Day 57, n=103.635 ± 26.884
GSK2391220, Day 1, n=96.820 ± 22.096
GSK2391220, Day 57, n=47.447 ± 7.539
GSK2487818, Day 1, n=203.388 ± 22.165
GSK2487818, Day 57, n=133.524 ± 32.634
GSK2506102, Day 1, n=18.530 ± NA
GSK2506102, Day 57, n=32NA ± NA
GSK2506104, Day 1, n=16.150 ± NA
GSK2506104, Day 57, n=32NA ± NA
GSK2531398, Day 1, n=115.582 ± 22.955
GSK2531398, Day 57, n=96.182 ± 14.307
GSK2531401, Day 1, n=44NA ± NA
GSK2531401, Day 57, n=32NA ± NA
SecondaryArea Under Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401

Blood samples were collected at indicated time points for pharmacokinetic analysis of daprodustat and its metabolites GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401. PK parameters were analyzed using standard non-compartmental analysis.

Time frame:
Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and 24 hours on Days 1 and 57
Reported as:
Geometric mean · Hour*nanograms per milliliter
Area Under Concentration-time Curve From Time Zero to 24 Hours (AUC[0-24]) of Daprodustat, GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401
Hour*nanograms per milliliterDaprodustat
Daprodustat, Day 1, n=42767.95 ± 125.63
Daprodustat, Day 57, n=28616.12 ± 168.05
GSK2391220, Day 1, n=42483.12 ± 60.42
GSK2391220, Day 57, n=31516.59 ± 61.78
GSK2487818, Day 1, n=41177.39 ± 66.83
GSK2487818, Day 57, n=28171.09 ± 93.41
GSK2506102, Day 1, n=42166.89 ± 52.93
GSK2506102, Day 57, n=31199.85 ± 44.33
GSK2506104, Day 1, n=42662.23 ± 54.48
GSK2506104, Day 57, n=31756.39 ± 50.29
GSK2531398, Day 1, n=42204.02 ± 59.48
GSK2531398, Day 57, n=31212.04 ± 66.63
GSK2531401, Day 1, n=42334.86 ± 93.49
GSK2531401, Day 57, n=31430.10 ± 73.53
Other pre-specifiedNumber of Participants With Any Serious Adverse Events (SAEs)

Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly or birth defect or any other situation according to medical or scientific judgment was categorized as SAE.

Time frame:
Up to Week 10
Reported as:
Count of participants · Participants
Number of Participants With Any Serious Adverse Events (SAEs)
ParticipantsDaprodustatRecombinant Human Erythropoietin
Number of Participants With Any Serious Adverse Events (SAEs)105
Other pre-specifiedNumber of Participants With Treatment Emergent Common (>=2%) Non-serious Adverse Events (Non-SAEs)

An AE is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship with study treatment. Number of participants with treatment emergent common (\>=2% non-SAEs in each arm) non-SAEs has been presented.

Time frame:
Up to Week 8
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Common (>=2%) Non-serious Adverse Events (Non-SAEs)
ParticipantsDaprodustatRecombinant Human Erythropoietin
Number of Participants With Treatment Emergent Common (>=2%) Non-serious Adverse Events (Non-SAEs)104
Other pre-specifiedNumber of Participants Who Discontinued the Study Treatment

Number of participants who discontinued the study treatment due to any reason are presented. The reasons for discontinuation included adverse events, protocol specified withdrawal criteria met, physician decision and withdrawal by participant.

Time frame:
Up to Week 10
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued the Study Treatment
ParticipantsDaprodustatRecombinant Human Erythropoietin
Adverse event22
Protocol-specified withdrawal criteria met74
Physician decision11
Withdrawal by participant30
Other pre-specifiedAbsolute Values for Clinical Chemistry Parameters: Albumin and Protein

Blood samples were collected for the analysis of clinical chemistry parameters including albumin and protein. Baseline value (Day1) is the latest non-missing pre-dose assessment.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · Grams per liter
Absolute Values for Clinical Chemistry Parameters: Albumin and Protein
Grams per literDaprodustatRecombinant Human Erythropoietin
Albumin, Baseline (Day1), n=45, 4341.2 ± 3.4240.5 ± 4.21
Albumin, Day 29, n=37, 4039.1 ± 3.5838.3 ± 4.02
Albumin, Day 57, n=31, 3541.4 ± 4.3540.9 ± 4.83
Albumin, Week 10, n=39, 3838.7 ± 3.2038.0 ± 5.19
Protein, Baseline (Day 1), n=45, 4372.3 ± 7.2772.6 ± 8.30
Protein, Day 29, n=37, 4069.4 ± 5.6768.0 ± 7.92
Protein, Day 57, n=31, 3574.0 ± 7.5173.1 ± 8.59
Protein, Week 10, n=39, 3867.5 ± 5.6767.8 ± 7.79
Other pre-specifiedAbsolute Values for Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)

Blood samples were collected for the analysis of clinical chemistry parameters including ALP, ALT and AST. Baseline value (Day1) is the latest non-missing pre-dose assessment.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · International units per liter
Absolute Values for Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)
International units per literDaprodustatRecombinant Human Erythropoietin
ALP, Baseline (Day1), n=45, 43100.9 ± 51.78100.0 ± 40.47
ALP, Day 29, n=37, 40104.4 ± 49.9795.7 ± 37.28
ALP, Day 57, n=31, 35109.0 ± 48.09101.7 ± 37.81
ALP, Week 10, n=42, 4198.3 ± 54.6498.8 ± 40.03
ALT, Baseline (Day 1), n=45, 4313.8 ± 6.7415.0 ± 6.97
ALT, Day 29, n=37, 4010.4 ± 3.9512.0 ± 5.80
ALT, Day 57, n=31, 3511.0 ± 5.7512.9 ± 5.07
ALT, Week 10, n=42, 4110.6 ± 4.7112.3 ± 7.01
AST, Baseline (Day 1), n=45, 4316.8 ± 6.6317.0 ± 6.07
AST, Day 29, n=37, 4013.2 ± 4.7613.7 ± 5.68
AST, Day 57, n=31, 3514.9 ± 5.1215.2 ± 4.23
AST, Week 10, n=42, 4114.0 ± 5.1815.2 ± 10.86
Other pre-specifiedAbsolute Values for Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin and Indirect (Indrt) Bilirubin

Blood samples were collected for the analysis of clinical chemistry parameters including direct bilirubin, total bilirubin and Indrt bilirubin. Baseline value (Day1) is the latest non-missing pre-dose assessment.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · Micromoles per liter
Absolute Values for Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin and Indirect (Indrt) Bilirubin
Micromoles per literDaprodustatRecombinant Human Erythropoietin
Direct bilirubin,Baseline(Day1),n=45,432.0 ± 1.241.8 ± 1.17
Direct bilirubin, Day 29, n=37, 391.9 ± 1.051.7 ± 1.23
Direct bilirubin, Day 57, n=31, 351.9 ± 1.211.8 ± 1.35
Direct bilirubin, Week 10, n=39, 381.8 ± 0.891.7 ± 1.09
Total bilirubin, Baseline (Day 1),n=45,438.6 ± 3.077.7 ± 3.25
Total bilirubin, Day 29, n=37, 397.1 ± 2.197.2 ± 1.93
Total bilirubin, Day 57, n=31, 359.0 ± 3.868.6 ± 2.69
Total bilirubin, Week 10, n=42, 417.7 ± 2.297.0 ± 2.20
Indrt bilirubin, Baseline (Day 1), n=45,436.6 ± 2.286.0 ± 2.74
Indrt bilirubin, Day 29, n=37, 395.2 ± 1.795.4 ± 1.89
Indrt bilirubin, Day 57, n=31, 357.0 ± 3.306.9 ± 2.02
Indrt bilirubin, Week 10, n=39, 385.9 ± 2.085.3 ± 1.83
Other pre-specifiedAbsolute Values for Clinical Chemistry Parameters: Calcium Corrected for Albumin (CCA), Glucose, Potassium, Phosphate and Sodium

Blood samples were collected for the analysis of clinical chemistry parameters including CCA, glucose, potassium, phosphate and sodium. Baseline value (Day1) is the latest non-missing pre-dose assessment.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · Millimoles per liter
Absolute Values for Clinical Chemistry Parameters: Calcium Corrected for Albumin (CCA), Glucose, Potassium, Phosphate and Sodium
Millimoles per literDaprodustatRecombinant Human Erythropoietin
CCA, Baseline (Day 1),n=45,432.254 ± 0.11472.266 ± 0.1341
CCA, Day 29, n=37, 402.242 ± 0.16922.242 ± 0.1479
CCA, Day 57, n=31, 352.240 ± 0.13892.265 ± 0.1086
CCA, Week 10, n=39, 382.227 ± 0.15992.232 ± 0.1644
Glucose, Baseline (Day 1), n=45,437.40 ± 2.7947.67 ± 3.504
Glucose, Day 29, n=37, 408.28 ± 4.2347.35 ± 2.362
Glucose, Day 57, n=31, 357.27 ± 2.4197.01 ± 2.690
Glucose, Week 10, n=39, 387.98 ± 3.0207.36 ± 2.948
Potassium, Baseline (Day 1), n=45,433.99 ± 0.5094.06 ± 0.788
Potassium, Day 29, n=37, 404.39 ± 0.7694.60 ± 0.765
Potassium, Day 57, n=31, 353.81 ± 0.4144.01 ± 0.663
Potassium, Week 10, n=39, 384.66 ± 0.6394.65 ± 0.693
Phosphate, Baseline (Day 1), n=45,431.129 ± 0.47921.242 ± 0.5758
Phosphate, Day 29, n=37, 401.455 ± 0.52071.761 ± 0.6297
Phosphate, Day 57, n=31, 350.953 ± 0.25231.274 ± 0.6260
Phosphate, Week 10, n=39, 381.629 ± 0.5601.849 ± 0.5431
Sodium, Baseline (Day 1), n=45,43137.9 ± 2.64138.0 ± 2.58
Sodium, Day 29, n=37, 40137.8 ± 2.41138.4 ± 2.84
Sodium, Day 57, n=31, 35137.7 ± 2.22138.6 ± 2.74
Sodium, Week 10, n=39, 38137.9 ± 2.28138.6 ± 2.77
Other pre-specifiedChange From Baseline Values for Clinical Chemistry Parameters: Albumin and Protein

Blood samples were collected for the analysis of clinical chemistry parameters including albumin and protein. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · Grams per liter
Change From Baseline Values for Clinical Chemistry Parameters: Albumin and Protein
Grams per literDaprodustatRecombinant Human Erythropoietin
Albumin, Day 29, n=37, 40-2.2 ± 3.67-2.4 ± 3.42
Albumin, Day 57, n=31, 350.4 ± 3.600.5 ± 3.16
Albumin, Week 10, n=39, 38-2.9 ± 3.10-2.4 ± 3.93
Protein, Day 29, n=37, 40-3.7 ± 6.41-4.7 ± 6.03
Protein, Day 57, n=31, 351.2 ± 6.440.7 ± 5.64
Protein, Week 10, n=39, 38-5.2 ± 5.90-4.9 ± 5.69
Other pre-specifiedChange From Baseline Values for Clinical Chemistry Parameters: ALP, ALT and AST

Blood samples were collected for the analysis of clinical chemistry parameters including ALP, ALT and AST. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · International units per liter
Change From Baseline Values for Clinical Chemistry Parameters: ALP, ALT and AST
International units per literDaprodustatRecombinant Human Erythropoietin
ALP, Day 29, n=37, 40-3.4 ± 19.56-5.3 ± 27.57
ALP, Day 57, n=31, 350.5 ± 23.213.4 ± 17.93
ALP, Week 10, n=42, 41-4.5 ± 29.46-1.9 ± 25.70
ALT, Day 29, n=37, 40-3.2 ± 5.74-2.6 ± 6.36
ALT, Day 57, n=31, 35-3.1 ± 7.93-1.9 ± 5.93
ALT, Week 10, n=42, 41-3.3 ± 7.31-2.8 ± 4.96
AST, Day 29, n=37, 40-3.2 ± 4.90-3.0 ± 5.38
AST, Day 57, n=31, 35-2.1 ± 6.10-1.9 ± 4.60
AST, Week 10, n=42, 41-3.3 ± 6.10-2.0 ± 9.11
Other pre-specifiedChange From Baseline Values for Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin and Indrt. Bilirubin

Blood samples were collected for the analysis of clinical chemistry parameters including direct bilirubin, total bilirubin and indrt. bilirubin. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · Micromoles per liter
Change From Baseline Values for Clinical Chemistry Parameters: Direct Bilirubin, Total Bilirubin and Indrt. Bilirubin
Micromoles per literDaprodustatRecombinant Human Erythropoietin
Direct bilirubin, Day 29, n=37, 39-0.1 ± 1.05-0.1 ± 1.69
Direct bilirubin, Day 57, n=31, 35-0.1 ± 1.21-0.1 ± 1.37
Direct bilirubin, Week 10, n=39, 38-0.3 ± 1.14-0.1 ± 1.18
Total bilirubin, Day 29, n=37, 39-1.5 ± 2.19-0.8 ± 3.10
Total bilirubin, Day 57, n=31, 350.6 ± 2.740.7 ± 2.70
Total bilirubin, Week 10, n=42, 41-1.0 ± 2.62-0.8 ± 2.23
Indrt bilirubin, Day 29, n=37, 39-1.4 ± 2.06-0.7 ± 2.92
Indrt bilirubin, Day 57, n=31, 350.6 ± 2.800.9 ± 2.80
Indrt bilirubin, Week 10, n=39, 38-0.8 ± 2.28-0.5 ± 2.01
Other pre-specifiedChange From Baseline Values for Clinical Chemistry Parameters: CCA, Glucose, Potassium, Phosphate and Sodium

Blood samples were collected for the analysis of clinical chemistry parameters including CCA, glucose, potassium, phosphate and sodium. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · Millimoles per liter
Change From Baseline Values for Clinical Chemistry Parameters: CCA, Glucose, Potassium, Phosphate and Sodium
Millimoles per literDaprodustatRecombinant Human Erythropoietin
CCA, Day 29, n=37, 400.000 ± 0.1384-0.021 ± 0.1699
CCA, Day 57, n=31, 350.004 ± 0.1344-0.000 ± 0.1450
CCA, Week 10, n=39, 38-0.010 ± 0.1693-0.033 ± 0.1284
Glucose, Day 29, n=37, 400.75 ± 4.331-0.48 ± 3.771
Glucose, Day 57, n=31, 35-0.45 ± 2.403-0.83 ± 2.684
Glucose, Week 10, n=39, 380.62 ± 3.001-0.18 ± 2.916
Potassium, Day 29, n=37, 400.45 ± 0.7900.53 ± 0.863
Potassium, Day 57, n=31, 35-0.14 ± 0.512-0.04 ± 0.696
Potassium, Week 10, n=39, 380.67 ± 0.6940.58 ± 0.746
Phosphate, Day 29, n=37, 400.389 ± 0.68760.513 ± 0.7270
Phosphate, Day 57, n=31, 35-0.123 ± 0.46240.004 ± 0.5274
Phosphate, Week 10, n=39, 380.505 ± 0.70160.599 ± 0.6723
Sodium, Day 29, n=37, 40-0.1 ± 3.250.3 ± 3.22
Sodium, Day 57, n=31, 350.2 ± 2.470.6 ± 2.71
Sodium, Week 10, n=39, 38-0.2 ± 2.410.5 ± 2.53
Other pre-specifiedAbsolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes

Blood samples were collected for the analysis of hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Baseline value (Day1) is the latest non-missing pre-dose assessment.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · 10^9 cells per liter
Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes
10^9 cells per literDaprodustatRecombinant Human Erythropoietin
Basophils, Baseline (Day 1), n=45, 410.050 ± 0.02950.044 ± 0.0255
Basophils, Day 29, n=37, 390.045 ± 0.03010.054 ± 0.0312
Basophils, Day 57, n=30, 350.049 ± 0.03490.045 ± 0.0243
Basophils, Week 10, n=39, 380.044 ± 0.02610.054 ± 0.0284
Eosinophils, Baseline (Day 1), n=45, 410.196 ± 0.15200.229 ± 0.2324
Eosinophils, Day 29, n=37, 390.238 ± 0.23010.191 ± 0.1551
Eosinophils, Day 57, n=30, 350.218 ± 0.18110.160 ± 0.1505
Eosinophils, Week 10, n=39, 380.231 ± 0.19180.184 ± 0.1167
Lymphocytes, Baseline (Day 1), n=45, 411.257 ± 0.39261.307 ± 0.6305
Lymphocytes, Day 29, n=37, 391.385 ± 0.54461.436 ± 0.5798
Lymphocytes, Day 57, n=30, 351.209 ± 0.50621.225 ± 0.6698
Lymphocytes, Week 10, n=39, 381.367 ± 0.55591.408 ± 0.6788
Monocytes, Baseline (Day 1), n=45, 410.398 ± 0.14710.408 ± 0.1752
Monocytes, Day 29, n=37, 390.442 ± 0.16640.460 ± 0.1812
Monocytes, Day 57, n=30, 350.432 ± 0.16210.448 ± 0.2204
Monocytes, Week 10, n=39, 380.469 ± 0.16400.443 ± 0.1773
Neutrophils, Baseline (Day 1), n=45, 414.091 ± 1.65714.053 ± 1.4574
Neutrophils, Day 29, n=37, 394.319 ± 1.35094.242 ± 1.5623
Neutrophils, Day 57, n=30, 354.381 ± 1.99264.377 ± 1.6450
Neutrophils, Week 10, n=39, 384.250 ± 1.81234.369 ± 1.7463
Platelets, Baseline (Day 1), n=45, 42188.5 ± 67.64193.8 ± 70.03
Platelets, Day 29, n=37, 38195.2 ± 66.55222.1 ± 82.78
Platelets, Day 57, n=30, 34207.8 ± 95.04213.5 ± 67.33
Platelets, Week 10, n=39, 38209.3 ± 75.61229.5 ± 78.29
Leukocytes, Baseline (Day 1), n=45, 416.00 ± 1.9236.04 ± 1.897
Leukocytes, Day 29, n=37, 396.43 ± 1.6786.38 ± 2.145
Leukocytes, Day 57, n=30, 356.29 ± 2.3636.25 ± 2.044
Leukocytes, Week 10, n=39, 386.35 ± 2.1786.45 ± 2.297
Other pre-specifiedAbsolute Values for Hematology Parameter: Hematocrit

Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value (Day1) is the latest non-missing pre-dose assessment.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · Proportion of red blood cells in blood
Absolute Values for Hematology Parameter: Hematocrit
Proportion of red blood cells in bloodDaprodustatRecombinant Human Erythropoietin
Baseline (Day 1), n=45, 420.3133 ± 0.031110.3242 ± 0.03046
Day 29, n=37, 390.3066 ± 0.031950.3113 ± 0.03307
Day 57, n=31, 350.3196 ± 0.030460.3397 ± 0.02476
Week 10, n=39, 380.3050 ± 0.037430.3209 ± 0.03375
Other pre-specifiedAbsolute Values for Hematology Parameters: Erythrocytes and Reticulocytes

Blood samples were collected for the analysis of hematology parameters: erythrocytes and reticulocytes. Baseline value (Day1) is the latest non-missing pre-dose assessment.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · 10^12 cells per liter
Absolute Values for Hematology Parameters: Erythrocytes and Reticulocytes
10^12 cells per literDaprodustatRecombinant Human Erythropoietin
Erythrocytes, Baseline (Day 1), n=45, 423.31 ± 0.3783.45 ± 0.388
Erythrocytes, Day 29, n=37, 393.20 ± 0.3613.27 ± 0.499
Erythrocytes, Day 57, n=31, 353.34 ± 0.3933.53 ± 0.357
Erythrocytes, Week 10, n=39, 383.13 ± 0.3883.38 ± 0.470
Reticulocytes, Baseline (Day 1), n=45, 420.0302 ± 0.015360.0401 ± 0.02614
Reticulocytes, Day 29, n=37, 390.0486 ± 0.016760.0733 ± 0.03493
Reticulocytes, Day 57, n=31, 350.0489 ± 0.016810.0627 ± 0.03344
Reticulocytes, Week 10, n=39, 380.0613 ± 0.039320.0566 ± 0.03060
Other pre-specifiedAbsolute Values for Hematology Parameters: Hemoglobin and Erythrocyte Mean Corpusclar Hemoglobin Concentration ( Ery. MCHC)

Blood samples were collected for the analysis of hematology parameters: hemoglobin and ery.MCHC. Baseline value (Day1) is the latest non-missing pre-dose assessment.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · Grams per liter
Absolute Values for Hematology Parameters: Hemoglobin and Erythrocyte Mean Corpusclar Hemoglobin Concentration ( Ery. MCHC)
Grams per literDaprodustatRecombinant Human Erythropoietin
Hemoglobin, Baseline (Day 1), n=45, 42102.2 ± 9.15104.5 ± 8.83
Hemoglobin, Day 29, n=37, 39100.2 ± 10.0199.7 ± 9.63
Hemoglobin, Day 57, n=31, 35105.2 ± 9.61107.9 ± 6.01
Hemoglobin, Week 10, n=39, 3899.6 ± 12.44102.9 ± 10.54
ery.MCHC, Baseline (Day 1), n=45, 42326.7 ± 9.01322.6 ± 8.41
ery.MCHC, Day 29, n=37, 39327.1 ± 6.57320.8 ± 11.50
ery.MCHC, Day 57, n=31, 35329.0 ± 6.62318.3 ± 15.46
ery.MCHC, Week 10, n=39, 38326.7 ± 9.26320.6 ± 9.17
Other pre-specifiedAbsolute Values for Hematology Parameter: Ery. Mean Corpuscular Hemoglobin (MCH) and Reticulocyte Corpuscular Hemoglobin Content (CHr)

Blood samples were collected for the analysis of hematology parameter: ery.MCH and CHr. Baseline value (Day1) is the latest non-missing pre-dose assessment.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · Picograms
Absolute Values for Hematology Parameter: Ery. Mean Corpuscular Hemoglobin (MCH) and Reticulocyte Corpuscular Hemoglobin Content (CHr)
PicogramsDaprodustatRecombinant Human Erythropoietin
ery. MCH, Baseline (Day 1), n=45, 4231.03 ± 2.29530.57 ± 2.880
ery. MCH, Day 29, n=37, 3931.56 ± 2.30230.83 ± 3.051
ery. MCH, Day 57, n=31, 3531.75 ± 2.31230.88 ± 3.140
ery. MCH, Week 10, n=39, 3831.96 ± 2.24630.66 ± 2.823
CHr, Baseline (Day 1), n=45, 4330.70 ± 1.73029.97 ± 2.088
CHr, Day 29, n=36, 4030.55 ± 1.79930.19 ± 2.242
CHr, Day 57, n=32, 3630.71 ± 1.85229.85 ± 2.462
CHr, Week 10, n=39, 3930.55 ± 2.11629.76 ± 2.079
Other pre-specifiedAbsolute Values for Hematology Parameter: Ery. Mean Corpuscular Volume (MCV)

Blood samples were collected for the analysis of hematology parameter: ery.MCV. Baseline value (Day1) is the latest non-missing pre-dose assessment.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · Femtoliters
Absolute Values for Hematology Parameter: Ery. Mean Corpuscular Volume (MCV)
FemtolitersDaprodustatRecombinant Human Erythropoietin
Baseline (Day 1), n=45, 4295.0 ± 6.3394.8 ± 8.37
Day 29, n=37, 3996.5 ± 6.9296.2 ± 8.76
Day 57, n=31, 3596.5 ± 7.1897.1 ± 9.04
Week 10, n=39, 3897.9 ± 6.6195.7 ± 8.37
Other pre-specifiedAbsolute Values for Hematology Parameter: Erythrocyte Distribution Width

Blood samples were collected for the analysis of hematology parameter: erythrocyte distribution width. Baseline value (Day1) is the latest non-missing pre-dose assessment.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · Percentage of width
Absolute Values for Hematology Parameter: Erythrocyte Distribution Width
Percentage of widthDaprodustatRecombinant Human Erythropoietin
Baseline (Day 1), n=45, 4216.06 ± 1.61815.71 ± 1.917
Day 29, n=37, 3916.52 ± 1.80216.75 ± 2.230
Day 57, n=31, 3516.11 ± 1.47616.67 ± 2.034
Week 10, n=39, 3816.42 ± 2.03616.45 ± 1.696
Other pre-specifiedChange From Baseline Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes

Blood samples were collected for the analysis of hematology parameters including basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and leukocytes. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · 10^9 cells per liter
Change From Baseline Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets and Leukocytes
10^9 cells per literDaprodustatRecombinant Human Erythropoietin
Basophils, Day 29, n=37, 37-0.007 ± 0.03170.010 ± 0.0329
Basophils, Day 57, n=30, 33-0.002 ± 0.03310.004 ± 0.0335
Basophils, Week 10, n=39, 36-0.004 ± 0.03490.009 ± 0.0323
Eosinophils, Day 29, n=37, 370.040 ± 0.1717-0.039 ± 0.1728
Eosinophils, Day 57, n=30, 330.016 ± 0.1513-0.038 ± 0.1202
Eosinophils, Week 10, n=39, 360.042 ± 0.1435-0.036 ± 0.1702
Lymphocytes, Day 29, n=37, 370.095 ± 0.36130.102 ± 0.4154
Lymphocytes, Day 57, n=30, 33-0.090 ± 0.3036-0.099 ± 0.3277
Lymphocytes, Week 10, n=39, 360.103 ± 0.38930.078 ± 0.4660
Monocytes, Day 29, n=37, 370.033 ± 0.16000.035 ± 0.1266
Monocytes, Day 57, n=30, 330.024 ± 0.16210.025 ± 0.1543
Monocytes, Week 10, n=39, 360.070 ± 0.13980.053 ± 0.1248
Neutrophils, Day 29, n=37, 370.071 ± 1.17060.061 ± 1.3382
Neutrophils, Day 57, n=30, 330.081 ± 1.22910.325 ± 1.1549
Neutrophils, Week 10, n=39, 360.218 ± 1.30960.181 ± 0.9586
Platelets, Day 29, n=37, 370.6 ± 31.1222.7 ± 52.46
Platelets, Day 57, n=30, 3313.9 ± 47.0416.4 ± 39.51
Platelets, Week 10, n=39, 3720.6 ± 36.0826.3 ± 41.87
Leukocytes, Day 29, n=37, 370.23 ± 1.2960.17 ± 1.555
Leukocytes, Day 57, n=30, 330.02 ± 1.4560.21 ± 1.231
Leukocytes, Week 10, n=39, 360.42 ± 1.4420.28 ± 1.220
Other pre-specifiedChange From Baseline Values for Hematology Parameter: Hematocrit

Blood samples were collected for the analysis of hematology parameter: hematocrit. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline Values for Hematology Parameter: Hematocrit
Proportion of red blood cells in bloodDaprodustatRecombinant Human Erythropoietin
Day 29, n=37, 38-0.0131 ± 0.03062-0.0136 ± 0.02614
Day 57, n=31, 34-0.0016 ± 0.037170.0131 ± 0.03609
Week 10, n=39, 37-0.0096 ± 0.04571-0.0054 ± 0.04944
Other pre-specifiedChange From Baseline Values for Hematology Parameters: Erythrocytes and Reticulocytes

Blood samples were collected for the analysis of hematology parameters: erythrocytes and reticulocytes. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · 10^12 cells per liter
Change From Baseline Values for Hematology Parameters: Erythrocytes and Reticulocytes
10^12 cells per literDaprodustatRecombinant Human Erythropoietin
Erythrocytes, Day 29, n=37, 38-0.17 ± 0.331-0.20 ± 0.273
Erythrocytes, Day 57, n=31, 34-0.06 ± 0.4100.04 ± 0.307
Erythrocytes, Week 10, n=39, 37-0.18 ± 0.488-0.11 ± 0.497
Reticulocytes, Day 29, n=37, 380.0156 ± 0.014320.0315 ± 0.03821
Reticulocytes, Day 57, n=31, 340.0169 ± 0.017090.0204 ± 0.02182
Reticulocytes, Week 10, n=39, 370.0314 ± 0.043850.0159 ± 0.02321
Other pre-specifiedChange From Baseline Values for Hematology Parameters: Hemoglobin and Ery. MCHC

Blood samples were collected for the analysis of hematology parameters: hemoglobin and ery.MCHC. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · Grams per liter
Change From Baseline Values for Hematology Parameters: Hemoglobin and Ery. MCHC
Grams per literDaprodustatRecombinant Human Erythropoietin
Hemoglobin, Day 29, n=37, 38-4.1 ± 9.35-5.1 ± 8.21
Hemoglobin, Day 57, n=31, 340.5 ± 10.602.5 ± 8.54
Hemoglobin, Week 10, n=39, 37-3.2 ± 14.35-1.8 ± 14.46
ery.MCHC, Day 29, n=37, 380.3 ± 8.41-2.0 ± 10.38
ery.MCHC, Day 57, n=31, 342.3 ± 8.83-4.4 ± 14.46
ery.MCHC, Week 10, n=39, 37-0.6 ± 9.37-0.8 ± 11.20
Other pre-specifiedChange From Baseline Values for Hematology Parameters: Ery. MCH and CHr

Blood samples were collected for the analysis of hematology parameter: ery.MCH and CHr. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · Picograms
Change From Baseline Values for Hematology Parameters: Ery. MCH and CHr
PicogramsDaprodustatRecombinant Human Erythropoietin
ery. MCH, Day 29, n=37, 380.39 ± 0.6760.40 ± 0.672
ery. MCH, Day 57, n=31, 340.70 ± 1.1610.49 ± 0.871
ery. MCH, Week 10, n=39, 370.78 ± 1.2490.38 ± 1.000
CHr, Day 29, n=36, 40-0.23 ± 0.9370.20 ± 1.060
CHr, Day 57, n=32, 36-0.12 ± 1.067-0.09 ± 1.617
CHr, Week 10, n=39, 39-0.29 ± 1.696-0.03 ± 1.478
Other pre-specifiedChange From Baseline Values for Hematology Parameter: Ery. MCV

Blood samples were collected for the analysis of hematology parameter: ery.MCV. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · Femtoliters
Change From Baseline Values for Hematology Parameter: Ery. MCV
FemtolitersDaprodustatRecombinant Human Erythropoietin
Day 29, n=37, 381.2 ± 2.471.8 ± 3.32
Day 57, n=31, 341.5 ± 3.502.9 ± 3.54
Week 10, n=39, 372.7 ± 4.801.4 ± 3.62
Other pre-specifiedChange From Baseline Values for Hematology Parameter: Erythrocyte Distribution Width

Blood samples were collected for the analysis of hematology parameter: erythrocyte distribution width. Baseline value (Day1) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Days 29, 57 and Week 10
Reported as:
Mean · Percentage of width
Change From Baseline Values for Hematology Parameter: Erythrocyte Distribution Width
Percentage of widthDaprodustatRecombinant Human Erythropoietin
Day 29, n=37, 380.38 ± 1.1971.09 ± 1.435
Day 57, n=31, 340.12 ± 1.2620.85 ± 1.609
Week 10, n=39, 370.35 ± 1.9980.59 ± 1.650
Other pre-specifiedAbsolute Values for Electrocardiogram (ECG) Mean Heart Rate

Full 12-lead ECGs were obtained in supine position using an ECG machine to measure mean heart rate. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.

Time frame:
Baseline (Day 1-predose) and at Day 1: 24 hours; Day 57: pre-dose; Day 57: 24 hours and Week 10
Reported as:
Mean · Beats per minute
Absolute Values for Electrocardiogram (ECG) Mean Heart Rate
Beats per minuteDaprodustatRecombinant Human Erythropoietin
Baseline (Day 1-predose), n=45, 4372.2 ± 9.5273.6 ± 9.03
Day 1: 24 hours, n=40, 3871.6 ± 9.3874.8 ± 9.42
Day 57: predose, n=32, 3671.2 ± 8.5872.7 ± 9.47
Day 57: 24 hours, n=32, 3671.2 ± 8.2275.1 ± 9.12
Week 10, n=39, 4072.3 ± 10.0374.3 ± 9.53
Other pre-specifiedAbsolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval Corrected for Heart Rate (QTc) and QT Interval Corrected for Heart Rate Using Bazett's Formula (QTcB)

Full 12-lead ECGs were obtained in supine position using an ECG machine to measure ECG parameters: PR interval, QRS duration, QTc interval and QTcB. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.

Time frame:
Baseline (Day 1-predose) and at Day 1: 24 hours; Day 57: pre-dose; Day 57: 24 hours and Week 10
Reported as:
Mean · Milliseconds
Absolute Values for ECG Parameters: PR Interval, QRS Duration, QT Interval Corrected for Heart Rate (QTc) and QT Interval Corrected for Heart Rate Using Bazett's Formula (QTcB)
MillisecondsDaprodustatRecombinant Human Erythropoietin
PR interval, Baseline (Day 1-predose), n=45, 43156.5 ± 30.81160.5 ± 30.79
PR interval, Day 1: 24 hours, n=39, 38158.1 ± 30.26163.3 ± 34.38
PR interval, Day 57: predose, n=32, 35155.8 ± 27.69152.1 ± 26.90
PR interval, Day 57: 24 hours, n=32, 36156.4 ± 29.83160.3 ± 32.98
PR interval, Week 10, n=39, 40162.5 ± 29.19159.9 ± 31.16
QRS duration, Baseline (Day 1-predose), n=45, 43106.2 ± 18.40107.4 ± 16.22
QRS duration, Day 1: 24 hours, n=40, 38106.0 ± 17.31107.4 ± 17.85
QRS duration, Day 57: predose, n=32, 36106.7 ± 14.46112.4 ± 21.89
QRS duration, Day 57: 24 hours, n=32, 36106.4 ± 15.05111.0 ± 20.75
QRS duration, Week 10, n=39, 40108.5 ± 15.56109.1 ± 20.69
QTc interval, Baseline (Day 1-predose), n=9, 17440.6 ± 22.41429.4 ± 27.49
QTc interval, Day 1: 24 hours, n=7, 11446.1 ± 18.94424.7 ± 27.73
QTc interval, Day 57: predose, n=5, 8452.8 ± 13.92436.1 ± 21.72
QTc interval, Day 57: 24 hours, n=5, 8430.6 ± 14.84431.8 ± 31.98
QTc interval, Week 10, n=6, 10438.8 ± 13.01428.3 ± 31.87
QTcB, Baseline (Day 1-predose), n=45, 43448.0 ± 40.17445.6 ± 31.00
QTcB, Day 1: 24 hours, n=40, 38438.9 ± 35.02439.3 ± 25.64
QTcB, Day 57: predose, n=32, 36442.3 ± 38.12449.1 ± 32.58
QTcB, Day 57: 24 hours, n=32, 36437.4 ± 33.58442.0 ± 37.61
QTcB, Week 10, n=39, 39442.0 ± 37.28441.6 ± 28.11
Other pre-specifiedChange From Baseline Values for ECG Mean Heart Rate

Full 12-lead ECGs were obtained in supine position using an ECG machine to measure mean heart rate. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1-predose) and at Day 1: 24 hours; Day 57: pre-dose; Day 57: 24 hours and Week 10
Reported as:
Mean · Beats per minute
Change From Baseline Values for ECG Mean Heart Rate
Beats per minuteDaprodustatRecombinant Human Erythropoietin
Day 1: 24 hours, n=40, 38-0.6 ± 6.850.8 ± 5.61
Day 57: predose, n=32, 36-1.6 ± 7.250.1 ± 8.22
Day 57: 24 hours, n=32, 36-1.7 ± 6.582.5 ± 8.21
Week 10, n=39, 40-0.1 ± 9.010.4 ± 8.86
Other pre-specifiedChange From Baseline Values for ECG Parameters: PR Interval, QRS Duration, QTc and QTcB

Full 12-lead ECGs were obtained in supine position using an ECG machine to measure ECG parameters: PR interval, QRS duration, QTc interval and QTcB. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1-predose) and at Day 1: 24 hours; Day 57: pre-dose; Day 57: 24 hours and Week 10
Reported as:
Mean · Milliseconds
Change From Baseline Values for ECG Parameters: PR Interval, QRS Duration, QTc and QTcB
MillisecondsDaprodustatRecombinant Human Erythropoietin
PR interval, Day 1: 24 hours, n=39, 383.0 ± 11.021.9 ± 11.16
PR interval, Day 57: predose, n=32, 350.2 ± 17.58-3.9 ± 11.34
PR interval, Day 57: 24 hours, n=32, 360.8 ± 15.891.8 ± 13.03
PR interval, Week 10, n=39, 404.9 ± 15.211.2 ± 17.11
QRS duration, Day 1: 24 hours, n=40, 38-0.5 ± 7.600.0 ± 4.73
QRS duration, Day 57: predose, n=32, 360.3 ± 9.532.8 ± 15.01
QRS duration, Day 57: 24 hours, n=32, 360.0 ± 11.131.4 ± 13.22
QRS duration, Week 10, n=39, 400.8 ± 12.620.7 ± 18.38
QTc interval, Day 1: 24 hours, n=7, 112.1 ± 14.59-9.4 ± 14.87
QTc interval, Day 57: predose, n=4, 8-6.3 ± 20.141.0 ± 5.71
QTc interval, Day 57: 24 hours, n=4, 8-29.0 ± 31.89-3.4 ± 14.79
QTc interval, Week 10, n=6, 9-6.7 ± 25.15-10.3 ± 11.74
QTcB, Day 1: 24 hours, n=40, 38-7.0 ± 24.13-3.1 ± 12.31
QTcB, Day 57: predose, n=32, 36-7.0 ± 30.144.9 ± 12.36
QTcB, Day 57: 24 hours, n=32, 36-12.0 ± 29.93-2.2 ± 23.15
QTcB, Week 10, n=39, 39-7.2 ± 35.84-3.0 ± 15.34
Other pre-specifiedAbsolute Values for Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

Vital signs including SBP and DBP were measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.

Time frame:
Baseline (Day 1, predose) and at Day 1: 3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis
Reported as:
Mean · Millimeters of mercury
Absolute Values for Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Millimeters of mercuryDaprodustatRecombinant Human Erythropoietin
SBP, Baseline (Day1, predose), n=45, 43135.87 ± 20.813137.00 ± 16.547
SBP, Day 1: 3 hours, n=44, 43140.64 ± 18.183144.05 ± 22.184
SBP, Day1: 12 hours, n=44, 43142.05 ± 23.150143.56 ± 20.566
SBP, Day 1: 24 hours, n=41, 40140.24 ± 20.960142.05 ± 14.822
SBP, Day 29: pre-dialysis, n=38, 40143.05 ± 20.351148.10 ± 20.445
SBP, Day 29: post dialysis, n=38, 40130.97 ± 20.608141.93 ± 19.038
SBP, Day 57: pre-dialysis, n=32, 36142.75 ± 22.599151.53 ± 19.893
SBP, Day 57: post dialysis, n=32, 36135.66 ± 18.314141.64 ± 20.304
SBP, Day 57: 3 hours, n=32, 36140.94 ± 22.623148.06 ± 20.316
SBP, Day 57: 12 hours, n=32, 36130.47 ± 22.492145.47 ± 18.599
SBP, Day 57: 24 hours, n=32, 36143.78 ± 17.783144.83 ± 15.497
SBP, Week 10: pre-dialysis, n=42, 42142.71 ± 20.123147.12 ± 18.285
SBP, Week 10: post dialysis, n=41, 42138.73 ± 19.584136.74 ± 22.105
DBP, Baseline (Day1, predose), n=45, 4370.00 ± 10.96772.05 ± 11.307
DBP, Day 1: 3 hours, n=44, 4374.91 ± 12.67675.53 ± 11.701
DBP, Day1: 12 hours, n=44, 4377.11 ± 13.78477.19 ± 12.557
DBP, Day 1: 24 hours, n=41, 4074.22 ± 11.01076.18 ± 10.318
DBP, Day 29: pre-dialysis, n=38, 4071.92 ± 10.79477.95 ± 12.850
DBP, Day 29: post dialysis, n=38, 4069.47 ± 11.27273.30 ± 10.823
DBP, Day 57: pre-dialysis, n=32, 3672.69 ± 9.85576.69 ± 12.578
DBP, Day 57: post dialysis, n=32, 3671.47 ± 10.58672.56 ± 10.383
DBP, Day 57: 3 hours, n=32, 3672.44 ± 13.02375.72 ± 11.732
DBP, Day 57: 12 hours, n=32, 3667.38 ± 10.53675.94 ± 10.376
DBP, Day 57: 24 hours, n=32, 3676.44 ± 12.42574.81 ± 8.756
DBP, Week 10: pre-dialysis, n=42, 4273.86 ± 12.47975.83 ± 10.087
DBP, Week 10: post dialysis, n=41, 4271.05 ± 12.00869.52 ± 10.341
Other pre-specifiedAbsolute Values for Temperature

Temperature was measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.

Time frame:
Baseline (Day 1, predose) and at Day 1: 3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis
Reported as:
Mean · Degrees celsius
Absolute Values for Temperature
Degrees celsiusDaprodustatRecombinant Human Erythropoietin
Baseline (Day1, predose), n=45, 4336.456 ± 0.370836.442 ± 0.3692
Day 1: 3 hours, n=44, 4336.427 ± 0.348036.374 ± 0.3102
Day1: 12 hours, n=44, 4336.470 ± 0.403236.507 ± 0.4125
Day 1: 24 hours, n=41, 4036.459 ± 0.359836.380 ± 0.3539
Day 29: pre-dialysis, n=38, 4036.389 ± 0.354736.418 ± 0.3169
Day 29: post dialysis, n=38, 4036.316 ± 0.357636.380 ± 0.3040
Day 57: pre-dialysis, n=32, 3636.419 ± 0.368536.403 ± 0.3410
Day 57: post dialysis, n=32, 3636.384 ± 0.302836.378 ± 0.2977
Day 57: 3 hours, n=32, 3636.422 ± 0.306636.497 ± 0.4018
Day 57: 12 hours, n=32, 3636.525 ± 0.436336.414 ± 0.3474
Day 57: 24 hours, n=32, 3636.447 ± 0.336036.506 ± 0.3014
Week 10: pre-dialysis, n=42, 4236.414 ± 0.337536.383 ± 0.2469
Week 10: post dialysis, n=41, 4236.461 ± 0.376736.450 ± 0.2625
Other pre-specifiedAbsolute Values for Pulse Rate

Pulse rate was measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment.

Time frame:
Baseline (Day 1, predose) and at Day 1:3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis
Reported as:
Mean · Beats per minute
Absolute Values for Pulse Rate
Beats per minuteDaprodustatRecombinant Human Erythropoietin
Baseline (Day1, predose), n=45, 4372.09 ± 9.86076.19 ± 11.450
Day 1: 3 hours, n=44, 4372.48 ± 9.93176.21 ± 10.432
Day1: 12 hours, n=44, 4371.95 ± 9.10172.65 ± 9.564
Day 1: 24 hours, n=41, 4073.37 ± 10.49576.43 ± 8.388
Day 29: pre-dialysis, n=38, 4072.92 ± 11.75176.05 ± 8.688
Day 29: post dialysis, n=38, 4074.00 ± 10.05176.18 ± 11.437
Day 57: pre-dialysis, n=32, 3674.59 ± 12.79377.17 ± 10.997
Day 57: post dialysis, n=32, 3672.63 ± 10.35475.75 ± 9.927
Day 57: 3 hours, n=32, 3670.91 ± 11.36075.25 ± 9.755
Day 57: 12 hours, n=32, 3670.50 ± 11.25975.11 ± 9.858
Day 57: 24 hours, n=32, 3671.16 ± 10.09775.36 ± 7.650
Week 10: pre-dialysis, n=42, 4273.07 ± 10.74475.81 ± 9.823
Week 10: post dialysis, n=41, 4271.76 ± 10.13874.55 ± 11.096
Other pre-specifiedChange From Baseline Values for Vital Signs: SBP and DBP

Vital signs including SBP and DBP were measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1, predose) and at Day 1: 3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis
Reported as:
Mean · Millimeters of mercury
Change From Baseline Values for Vital Signs: SBP and DBP
Millimeters of mercuryDaprodustatRecombinant Human Erythropoietin
SBP, Day 1: 3 hours, n=44, 435.34 ± 20.3077.05 ± 18.639
SBP, Day1: 12 hours, n=44, 436.75 ± 25.6426.56 ± 17.633
SBP, Day 1: 24 hours, n=41, 403.90 ± 21.8466.23 ± 18.150
SBP, Day 29: pre-dialysis, n=38, 408.24 ± 27.06912.00 ± 25.314
SBP, Day 29: post dialysis, n=38, 40-3.84 ± 20.6765.83 ± 21.882
SBP, Day 57: pre-dialysis, n=32, 366.63 ± 25.12516.03 ± 20.492
SBP, Day 57: post dialysis, n=32, 36-0.47 ± 22.7476.14 ± 20.699
SBP, Day 57: 3 hours, n=32, 364.81 ± 22.93812.56 ± 20.832
SBP, Day 57: 12 hours, n=32, 36-5.66 ± 25.5759.97 ± 20.520
SBP, Day 57: 24 hours, n=32, 367.66 ± 21.9199.33 ± 22.080
SBP, Week 10: pre-dialysis, n=42, 427.36 ± 21.41210.48 ± 19.261
SBP, Week 10: post dialysis, n=41, 422.73 ± 19.0050.10 ± 23.472
DBP, Day 1: 3 hours, n=44, 435.07 ± 12.6173.49 ± 13.170
DBP, Day1: 12 hours, n=44, 437.27 ± 13.5885.14 ± 13.105
DBP, Day 1: 24 hours, n=41, 404.07 ± 13.1294.18 ± 11.569
DBP, Day 29: pre-dialysis, n=38, 402.63 ± 14.7495.88 ± 14.650
DBP, Day 29: post dialysis, n=38, 400.18 ± 13.8541.23 ± 12.259
DBP, Day 57: pre-dialysis, n=32, 362.94 ± 13.4575.86 ± 13.316
DBP, Day 57: post dialysis, n=32, 361.72 ± 11.2771.72 ± 12.230
DBP, Day 57: 3 hours, n=32, 362.69 ± 17.0874.89 ± 14.540
DBP, Day 57: 12 hours, n=32, 36-2.38 ± 13.7605.11 ± 14.186
DBP, Day 57: 24 hours, n=32, 366.69 ± 15.9953.97 ± 13.729
DBP, Week 10: pre-dialysis, n=42, 423.71 ± 13.3283.50 ± 12.975
DBP, Week 10: post dialysis, n=41, 421.00 ± 10.151-2.81 ± 12.934
Other pre-specifiedChange From Baseline Values for Temperature

Temperature was measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1, predose) and at Day 1: 3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis
Reported as:
Mean · Degrees celsius
Change From Baseline Values for Temperature
Degrees celsiusDaprodustatRecombinant Human Erythropoietin
Day 1: 3 hours, n=44, 43-0.027 ± 0.3744-0.067 ± 0.3220
Day1: 12 hours, n=44, 430.016 ± 0.40110.065 ± 0.3981
Day 1: 24 hours, n=41, 400.015 ± 0.3712-0.050 ± 0.3359
Day 29: pre-dialysis, n=38, 40-0.089 ± 0.5451-0.033 ± 0.3731
Day 29: post dialysis, n=38, 40-0.163 ± 0.4790-0.070 ± 0.4027
Day 57: pre-dialysis, n=32, 36-0.003 ± 0.4447-0.028 ± 0.4158
Day 57: post dialysis, n=32, 36-0.038 ± 0.3774-0.053 ± 0.3247
Day 57: 3 hours, n=32, 360.000 ± 0.40480.067 ± 0.4697
Day 57: 12 hours, n=32, 360.103 ± 0.5196-0.017 ± 0.3085
Day 57: 24 hours, n=32, 360.025 ± 0.45010.075 ± 0.3557
Week 10: pre-dialysis, n=42, 42-0.055 ± 0.4840-0.062 ± 0.4328
Week 10: post dialysis, n=41, 42-0.002 ± 0.52700.005 ± 0.4311
Other pre-specifiedChange From Baseline Values for Pulse Rate

Pulse rate was measured in participants in a semi-supine position after 5 minutes rest. Baseline (Day 1-predose) is the latest non-missing pre-dose assessment. Change from Baseline is defined as Post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1, predose) and at Day 1: 3, 12, 24 hours; Day 29: pre- and post-dialysis; Day 57: pre- and post-dialysis, 3, 12, 24 hours and Week 10: pre- and post-dialysis
Reported as:
Mean · Beats per minute
Change From Baseline Values for Pulse Rate
Beats per minuteDaprodustatRecombinant Human Erythropoietin
Day 1: 3 hours, n=44, 430.61 ± 7.7350.02 ± 10.859
Day1: 12 hours, n=44, 430.09 ± 8.232-3.53 ± 12.473
Day 1: 24 hours, n=41, 401.39 ± 10.954-0.35 ± 11.005
Day 29: pre-dialysis, n=38, 400.87 ± 9.3930.03 ± 10.850
Day 29: post dialysis, n=38, 401.95 ± 11.2030.15 ± 12.593
Day 57: pre-dialysis, n=32, 362.50 ± 10.5222.14 ± 10.805
Day 57: post dialysis, n=32, 360.53 ± 9.3080.72 ± 12.523
Day 57: 3 hours, n=32, 36-1.19 ± 11.9980.22 ± 12.547
Day 57: 12 hours, n=32, 36-1.59 ± 12.1040.08 ± 10.811
Day 57: 24 hours, n=32, 36-0.94 ± 11.4350.33 ± 10.368
Week 10: pre-dialysis, n=42, 421.33 ± 10.195-0.48 ± 13.457
Week 10: post dialysis, n=41, 42-0.54 ± 9.344-1.74 ± 11.232

Adverse events

Collected over Non-SAEs were reported from start of study treatment and up to 8 weeks in treatment period and SAEs were reported from the start of the study treatment and up to 2 weeks in follow up period (Up to Week 10).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Daprodustat0/45 (0%)10/45 (22.2%)10/45 (22.2%)
Recombinant Human Erythropoietin0/43 (0%)5/43 (11.6%)4/43 (9.3%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventDaprodustatRecombinant Human Erythropoietin
Fluid overloadMetabolism and nutrition disorders3/450/43
Hypertensive urgencyVascular disorders2/450/43
HypotensionVascular disorders2/450/43
PneumoniaInfections and infestations2/450/43
AnaemiaBlood and lymphatic system disorders2/450/43
HyperkalaemiaMetabolism and nutrition disorders0/451/43
Abdominal painGastrointestinal disorders0/451/43
Pulmonary oedemaRespiratory, thoracic and mediastinal disorders0/451/43
Non-cardiac chest painGeneral disorders0/451/43
Upper limb fractureInjury, poisoning and procedural complications0/451/43
Most frequent other events
Showing 10 of 20
Most frequent other events
EventDaprodustatRecombinant Human Erythropoietin
HeadacheNervous system disorders0/452/43
HypertensionVascular disorders0/452/43
Suspected COVID-19Infections and infestations0/451/43
DiarrhoeaGastrointestinal disorders0/451/43
NauseaGastrointestinal disorders0/451/43
VomitingGastrointestinal disorders0/451/43
AstheniaGeneral disorders0/451/43
DizzinessNervous system disorders1/450/43
ParaesthesiaNervous system disorders1/450/43
PresyncopeNervous system disorders1/450/43

Baseline characteristics

Age, Continuous
Age, Continuous(Years)DaprodustatRecombinant Human ErythropoietinTotal
Mean60.9 ± 11.0658.7 ± 10.6159.8 ± 10.84
Sex: Female, Male
Sex: Female, Male(Participants)DaprodustatRecombinant Human ErythropoietinTotal
Female191635
Male262753
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DaprodustatRecombinant Human ErythropoietinTotal
Black or African American212344
White-Arabic/North African Heritage101
White-White/Caucasian/European Heritage232043
08

Study locations

11 sites
  • GSK Investigational Site
    La Mesa, California 91942, United States
  • GSK Investigational Site
    Lakewood, Colorado 80228, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    DeLand, Florida 32720, United States
  • GSK Investigational Site
    Hollywood, Florida 33024, United States
  • GSK Investigational Site
    Miami, Florida 33133, United States
  • GSK Investigational Site
    Orlando, Florida 32809, United States
  • GSK Investigational Site
    Chicago, Illinois 60643, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55404, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29301, United States
  • GSK Investigational Site
    San Antonio, Texas 78215, United States
09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2017 to primary completion in Jul 2020, 35 months.

Results were first posted in Jun 2021, 10 months after primary completion.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 35 months is above that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2017
First posted
Jan 24, 2017
StartActual
Jul 27, 2017
Primary completionActual
Jul 9, 2020
CompletionActual
Jul 9, 2020
Results first posted
Jun 3, 2021
Last update
Jun 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03029247
Lead sponsor
GlaxoSmithKline
Collaborators
ERT: Clinical Trial Technology Solutions, Q2 Solutions, Quintiles, Inc., HemoCue
Responsible party
Sponsor
First posted
Jan 24, 2017
Start date
Jul 27, 2017
Primary completion
Jul 9, 2020
Completion
Jul 9, 2020
Results posted
Jun 3, 2021
Last update
Jun 3, 2021

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion